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Extracellular vesicles (EVs) are membrane vesicles secreted by cells and distributed 
widely in all biofluids. Extracellular vesicles can modulate the biological activities of the 
recipient cells. Due to their role in intercellular communication, they are receiving attention for 
therapeutic and diagnostic applications. The first step to better understand EVs and to utilize 
them as therapeutic and diagnostic tools is to purify them from a variety of biofluids. 
Membranes have been extensively used for purification of different biological species from 
biological fluids. As the first aim, a novel microfluidic system, termed as tangential flow for 
analyte capture (TFAC) was developed to isolate nanoparticles and EVs using ultrathin 
nanomembranes. Ultrathin nanomembranes were found well-suited for TFAC system when 
compared with conventional thickness membranes. TFAC also proved feasible for capturing of 
EVs from undiluted plasma.  
Fluorescent labeling of EVs has been employed for studying uptake and biodistribution 
of EVs. However, far too little attention has been paid to the effect of the fluorescent labeling 
on the size of EVs. In the second aim, the effect of PKH labeling, the most commonly used dye, 
on the size of EVs was systematically evaluated by nanoparticle tracking analysis (NTA). PKH 
labeling did not preserve the size of EVs and caused a size increase in all the PKH labeling 
conditions tested. The observed size shift may alter the uptake and biodistribution of EVs, 
suggesting that PKH labeling is not a reliable technique.  
Precise quantification and characterization of EVs is an important step towards utilizing 
them as therapeutic and diagnostic tools. EVs have been analyzed using bulk techniques such as 
western blot which is challenging due to the heterogeneity of EVs. Therefore, a robust and well-
established technique for quantification and characterization of individual EVs is required. As 
the third aim, the efficacy of a virus detection technology for EVs was evaluated. Virus Counter 
3100 (VC3100) is a fluorescence-based technique with similar principles as flow cytometry and 
was purpose-built for detection of small nanoparticles such as viruses. Due to the similarity in 
size and density of viruses and EVs in many biofluids, it was hypothesized that the VC3100 could 
detect EVs similarly to flow cytometry characterization of cells. Fluorescently labeled EVs from 
different sources were successfully quantified by the VC3100. Furthermore, VC3100 was also 
used to determine the expression level of target protein markers. Therefore, VC3100 is a 
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1.1 Extracellular Vesicles 
All cell types are capable of shedding membrane-enclosed vesicles called extracellular vesicles 
(EVs) which were initially proposed as a means of discarding a cell’s garbage [1]. However, two 
decades of research have provided evidence that EVs play a key role in intercellular 
communication and are more than just waste carriers [2]. EVs have been found from diverse 
bodily fluids including blood, urine, saliva, amniotic fluids, ascites, cerebrospinal fluid and 
breast milk [3,4]. Extracellular vesicles can be divided into three categories based on the 
current state of knowledge of their biogenesis; (i) Exosomes (ii) Microvesicles (iii) Apoptotic 
Bodies. A lipid bilayer membrane which encapsulates a cargo of biomolecules is the common 
feature in all the EV subtypes [2,5]. Exosomes (30-150 nm) are released via exocytosis from 
multivesicular bodies (MVBs) of the late endosome. Microvesicles (100 nm to 1 µm) directly 
bud from the cell’s plasma membrane. Apoptotic bodies (50 nm to 1 µm) are released by cells 
undergoing apoptosis [2,6,7]. However, EV subtypes cannot be solely discriminated on the basis 
of intrinsic properties such as size, buoyant density and protein composition.  
Extracellular vesicles (EVs) have received significant attention in recent decades due to their 
roles in physiological, therapeutic and pathological processes. EVs are known to be functionally 
involved in intercellular communications by various signaling pathways including delivery of 
cargo (RNA and proteins) into the recipient cells [2,8–10]. EVs in both unmodified and modified 
states have also been investigated as candidates for therapeutic agents in drug delivery 
applications [11,12]. From a clinical and diagnostic prospective, EVs are of interest as novel 
biomarkers for noninvasive detection and monitoring of diseases, since they are secreted in all 
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biological fluids such as blood, semen, urine, saliva and milk [5,13,14]. A comprehensive 
understanding of the EV properties will benefit their development as diagnostic and 




1.2 Purification of Extracellular Vesicles 
Interest in extracellular vesicles (EVs) for diagnostic and therapeutic applications has seen a 
meteoric rise in the past decade from biomarkers for breast, lung, and bladder cancer to drug 
delivery vehicles that can transport drugs across the blood-brain barrier [7,15–18]. Extracellular 
vesicles are found in all bodily fluids as well as cell culture supernatant [19]. However, in order 
to study these vesicles they must first be isolated. Despite the increasing clinical importance of 
EVs, current methods of EV isolation suffer from complicated procedures with long processing 
time [20]. The isolation of a pure population of EVs would facilitate studies regarding their 
physiological functions and their roles in various pathologies [21]. Additionally, contamination 
of EV preparations with non-EV proteins can lead to incorrect conclusions about their biological 
activities [22].   
The “gold standard” method for isolating EVs from biofluids is ultracentrifugation, which 
requires large volumes of biofluids (>25 mL), long processing times, expensive instrumentation 
and trained technicians. In order to eliminate the requirements of ultracentrifugation, 
commercial EV isolation kits have been developed (e.g. ExoQuick® or Total Exosome 
Isolation™). These precipitation based techniques are hydrogel net based methods that are 
useful for isolating EVs in small volumes. However, these nets are non-specific and will co-
precipitate proteins with the EVs [23]. Additionally, having intact EVs is very important for 
therapeutic applications, but these residual precipitation matrices could influence EVs 
biological activities [24,25]. Microfluidic devices have been developed to minimize the material 
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cost, energy consumption, sample sizes, and reaction time for isolation of EVs. The microfluidic-
based platforms for EV isolation can be divided into three categories;  
Immunoaffinity-based Techniques 
Immunoaffinity-based techniques use antibody coated “capture surfaces” or “capture beads” 
to target specific surface markers of EV subpopulations [26]. Two main types of platforms for 
EV isolation have been developed based on functionalizing the surface including devices with 
coated inner surface [27–29] and devices that use capture beads [30–32] with great advantages 
such as reduced isolation time and high purity. However, these techniques suffer from major 
limitations such as cost, sample pretreatment, and non-specific sorption of nontarget EVs. 
Furthermore, affinity-based methods are not suitable for diagnostic applications because of 
isolating only known surface antigens (not all the EVs) as well as concerns regarding having 
intact EVs after elution off the complexes with antibodies [33–35].  
Contact-free Techniques 
Contact-free isolation of EVs has been demonstrated with many different mechanisms such as 
acoustic microfluidics [36–38] and nanoscale deterministic lateral displacement (nDLD) [39,40]. 
Both acoustic and nDLD sorting techniques have been successfully used for size separation of 
micron scale particles. Breakthroughs from the micro [41,42] to nanoscale using these 
technologies have been recently reported with promising potential in separation of 
nanoparticles and EVs. Precise separation of cancer-derived microvesicles from EVs [39] as well 
as separation of colloids and EVs [40] have been demonstrated using nDLD technology. 
However, these fabricated dense nanostructures may also result in blockage and decrease the 
throughput of the device and further studies are needed [26,33,34]. Separation of EVs from 
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whole blood was observed in acoustic-based microfluidics in two steps; the cell-removal step to 
first remove larger blood components followed by the EV-isolation step to purify EVs [38]. 
However, higher throughput and evaluation of the robustness of acoustic-based platforms with 
various bodily fluids are necessary. Furthermore, the purification of EVs from proteins is still 
challenging and requires further studies [26,33,34].   
Filtration-based Techniques  
These techniques use membranes with different pore size to allow smaller particles to pass 
through the membrane and particles larger than selected pore size to be retained and isolated. 
Filtration-based microfluidics have been recently developed for EV isolation and analysis 
featuring at least double filtration [43–45]. Larger EVs and impurities from urine samples were 
retained by a 200 nm membrane while small EVs were enriched by a 30 nm membrane which 
allows the proteins to pass through [44]. The ExoDisc system employed 20 and 600 nm pore 
sizes which could decrease the purity due to co-isolation of larger EVs [45]. Both systems 
achieved high throughput and good recovery. However, filtration based separations have 
disadvantages such as blockage of the membrane by protein molecules and formed aggregates 
which are hard to remove and potential deformation of EVs while passing through the 
membrane due to pressure [34,46]. Membranes used in filtration systems are often ‘track-etch’ 
membranes [43–45] which are made of a polymer (e.g. PET, PTFE, polycarbonate) and the pores 
are generated using a charged particle etching technique. While these membranes are widely 
used, their thickness (often > 6 μm) means that they have high transmembrane pressures under 
flow conditions and they also have very low permeabilities [47,48].  
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1.3 Fluorescent Labeling of Extracellular Vesicles  
Since EVs are highly heterogeneous in their size, cargo, functional role and cells of origin, 
precise characterization and accurate imaging techniques are crucial for their diagnostic and 
therapeutic applications [49,50]. Advanced imaging and characterization technologies such as 
electron microscopy (EM) and atomic force microscopy (AFM) have been used for studying EVs, 
however challenges still exist due to the small size and complex nature of EVs [8,10]. Real-time 
imaging and tracking of EVs as well as direct and high throughput characterization are crucial 
and can provide valuable information in understanding the mechanisms at play during uptake 
and biodistribution. Fluorescent labeling of EVs has been employed to assist researchers in 




1.3.1 Applications of Fluorescent Labeling of EVs  
Using recent advances in fluorescent dyes for labeling EVs combined with high resolution 
characterization and imaging techniques, fluorescent labeling can be applied in the following 
studies:  
1.3.1.1 Uptake Studies  
Since cellular functions can be modulated by EVs under both physiological and pathological 
conditions, the distinct mechanisms and pathways associated with the uptake of EVs by 
recipient cells needs to be explored [8,51]. Moreover, EVs can also be utilized to increase 
functional cargo delivery for therapeutic and drug delivery applications [10,11]. In order to 
understand the role of EVs in intercellular communication by transporting cargo between close 
and distant cells, uptake studies are crucial. Uptake studies have been performed by studying 
co-localization of labeled EVs with fluorescently labeled plasma membranes or intracellular 
components such as endosome and nuclei of the recipient cells [52]. Using fluorescent labeling, 
the internalization of EVs has been reported by a wide range of recipient cells such as dermal 
fibroblasts [53], dendritic cells [54], macrophages [14], myocardial cells and endothelial cells 
[55]. Furthermore, It has been shown that EVs can be internalized through multiple routes 
including, phagocytosis, macropinocytosis, and receptor-mediated endocytosis and fusion using 
fluorescent labeling [9,12]. 
1.3.1.2 Biodistribution Studies 
Secreted EVs by various cell types can be found in secreted biological fluids as well as the 
circulation system [13,49]. Studying the fate of EVs in circulation can provide valuable 
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information about the dynamic biological behavior of EVs such as determining whether EVs are 
targeting specific tissues and subsequently being internalized by their recipient cells or are 
getting cleared in the blood [49,56]. Furthermore, recent studies have provided evidence that 
EVs can promote tumor progression which also shows the importance of evaluating distribution 
and clearance of tumor-derived EVs [10,11,15]. EVs have also received attention as therapeutic 
agents due to their inherent ability to carry various biomolecules (e.g. RNA and proteins), their 
effective transport of their cargo to recipients cells, and their reduced toxicity and 
immunogenicity compared to artificial delivery vehicles [12,49,57]. Therefore, investigating the 
in vivo distribution, accumulation and tracking of therapeutic EVs is desired for their safety and 
efficacy in therapeutic and drug delivery applications of EVs [56,58]. 
1.3.1.3 Characterization Studies 
The abundance of a specific EVs in biological fluids has been linked with various diseases and 
cancers such as and cardiovascular disease [59], lung [60], ovarian cancer [61], kidney and 
breast cancers [62], which makes them attractive candidates for biomarkers in non-invasive 
liquid biopsies [63,64]. Moreover, therapeutic applications of EVs have received significant 
attention by researchers recently to develop new treatments for cancer [13,65]. For both 
therapeutic and diagnostic applications of EVs, better understanding and knowledge of 
different subclasses and functional differences is required [12,13,65]. 
Molecular composition of EVs has been analyzed using bulk based techniques such as 
proteomics, lipidomics and western blot. However, small size and heterogeneity of EVs hamper 
these quantitative analyses [57,66]. Alternatively, single EV analysis techniques such as 
immunoelectron microscopy and atomic force microscopy have been applied to study 
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biomarker profiling and their potential clinical applications, but are still time consuming [64]. 
High-resolution flow cytometry has also been used for analyzing single EVs [67,68]. Small size 
and low refractive index of EVs is problematic in scattering based flow cytometry, which results 
in low sensitivity of the system [64,69,70]. Moreover, High background signal due to using 
sheath and sample buffers as well as the presence of non-EV artifacts is another challenge to 
resolve true biological EVs from instrument noise [13,71]. As an alternative, fluorescent based 
detection of EVs has been employed to analyze EVs which is independent of size, refractive 
index and is less affected by the background signal [63,65,71]. Nanoparticle tracking analysis 
(NTA) as a single EV analysis technique, has been applied to determine the size and 
concentration of EVs [63,65,71]. However, NTA quantitative analysis is less accurate in 
heterogeneous samples in terms of concentration and has limited ability to characterize 





1.3.2 EV Labeling Approaches  
EVs can be fluorescently labeled for uptake, biodistribution and characterization studies of EVs 
by different fluorescent dyes such as:  
1.3.2.1 Surface marker labeling of EVs:  
Proteins on the membrane surface can be fluorescently labeled to track cell-cell 
communication, determine their biodistribution and identify the phenotype subset of EVs by 
flow cytometry. Tetraspanins such as CD9, CD63 and CD81 are abundant on the surface of 
many EV types and are known as common markers of EVs, which have been labeled 
fluorescently using primary and secondary antibodies [72]. In addition, surface proteins on 
membranes of EVs can be also fluorescently labeled non-specifically by conjugating 
fluorophores with different functional groups such as TAMARA and Alexa Flour bound with N-
hydroxy succinimidyl (NHS) ester which covalently bond with amine groups on proteins [73,74].  
In addition to flow cytometry for identifying the phenotype subset of EVs, other techniques 
have been developed for single EV analysis [75]. Using a microfluidic device, the authors first 
captured EVs on the device surface coated with neutravidin. Then, captured EVs were labeled 
by fluorescent antibodies such as CD9, CD63 and CD81 and then imaged to identify their marker 
expression profile [75].  
1.3.2.2 Lipid Membrane Labeling of EVs:  
The plasma membrane of EVs can be labeled using lipophilic dyes. PKH family [64,76,77], 
DiI/DiR/DiD dyes [52,56,78], and FM dye [79], are commonly used lipid membrane dyes to label 
EVs due to their stable fluorescent signal and simple labeling process. Among lipid membrane 
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dyes, the PKH family has been the most extensively used dye for labeling EVs in uptake, 
biodistribution and flow cytometry characterization of EVs. PKH dyes are lipophilic long-chain 
carbocyanine dyes that rapidly intercalate into lipid structures (biological and artificial) and 
form noncovalent interactions leading to a bright and stable labeling [50,80]. 
One study reported biochemical evidences that the internalization of EVs derived from 
glioblastoma multiforme (GBM) cell line depends on cell-surface heparan sulfate proteoglycans 
[81]. The authors labeled GBM derived EVs with PKH26 and found a dose dependent and 
saturable internalization of EVs using flow cytometry and confocal fluorescence microscopy 
[81]. In another study, PKH labeling was employed to evaluate the interaction of platelet 
derived EVs with human brain endothelial cells using confocal microscopy and reported that the 
internalization is driven by endocytosis [76]. Moreover, The transfer mechanism of EVs was 
addressed from oligodendroglia cells to target cells and confocal microscopy analysis of PKH 
labeled EVs showed their internalization and transfer to late endosome and lysosome of 
microglia cells [82]. 
PKH labeling was also applied to investigate the effect of EVs derived from MSCs on an 
immune-induced liver model [83]. The authors observed co-localization of PKH and CD81 in the 
injured liver specimen and showed promising therapeutic potentials of MSC derived EVs [83]. 
Furthermore, therapeutic potentials of EVs were investigated as drug delivery carriers in a 
cancer model by labeling EVs with PKH67 and showed the uptake of EVs by breast cancer cell 
lines for 4 hours using flow cytometry and confocal electron microscopy [77]. Biodistribution of 
human cancer has been characterized by PKH labeling of cell-line-derived E in the lung and liver 
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of mice [84]. The authors used near infrared (NIR) whole-lung imaging of lung and fluorescent 
microscopy of lung, liver and brain to trace PKH-labeled EVs [84].  
PKH labeling has been also used for characterization of EVs using flow cytometry. A novel flow 
cytometry-based method was developed to quantify nanosized particles like EVs derived from 
Dendritic and T cells [64]. PKH family was also used to demonstrate the effect of non-EV 
particles in plasma which can lead to false positive signals using light scattering and even 
fluorescent detection of low-abundance PKH67 labeled EVs due to coincidence and swarm by 
fluorescence-based flow cytometry [71]. However, the authors identified potential solutions by 
monitoring the undesired particles in serial dilutions [71]. Another study provided a step by 
step protocol for quantitative and qualitative analysis of EVs by high resolution microscopy. The 
authors reported that PKH67 dye brightly labels EVs and can be detected above a fluorescent 
threshold that eliminates non-fluorescent noise [85]. 
1.3.2.3 Luminal labeling of EVs:  
The lumen of EVs can be fluorescently labeled using membrane permeable dyes such as the 
acetomethoxy derivative of calcein (Calcein AM) and carboxyfluorescein diacetate succinimidyl 
ester (CFDA-SE, hereinafter CFSE). These chemical compounds become fluorescent and EV-
impermeable in their hydrolyzed forms. Similar to cells, the presence of esterases inside EVs 
catalyzes the cleavage of CFSE acetate groups leading to fluorescent labeling of EVs [86]. 
CFSE labeling has been used to study the effect of lung derived EVs in the development of 
marrow cell-based cellular therapies, internalization of CFSE labeled EVs has been shown by 
stem/progenitor cells and different differentiated cell types such as granulocytes, B cells and 
erythroid cells using fluorescent microscopy [87]. In another study, CFSE labeled EVs were 
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incubated with prostate PC-3 tumor cells to investigate the effect of human bone marrow-
derived EVs on prostate cancer [88]. The authors observed localization of CFSE-labeled EVs in 
the cytoplasm of cancer cells in a time dependent manner suggesting uptake of EVs [88]. 
Different uptake mechanisms of labeled EVs has been also studied using immunofluorescence 
microscopy and flow cytometry analysis using CFSE labeled EVs derived from ovarian cancer 
cells [89]. Another group determined the target organelle after EV internalization by confocal 
microscopy and found colocalization of CFSE labeled EVs with endosomes and lysosomes 
suggesting their involvement in an endocytic pathway [52]. In another study, a novel and fast 
protocol was presented for quantification and characterization of EVs using CFSE labeling by a 
flow cytometer specifically designed for small particles [79]. Furthermore, the effect of particles 
concentration on the performance of the high resolution flow cytometry for EVs 
characterization was explored by CFSE as a generic labeling of EVs [13].  
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1.3.3  Post-labeling Clean-up 
In fluorescent based studies of EVs, there is always a concern that the signal detected is from 
unbound dye and not labeled EVs [78]. In uptake studies, the excess dye can interact with the 
recipient cells, which increases the background signal and can result in false positive events 
affecting the accuracy of the uptake studies [8,80,81,90]. A common approach to study the 
possibility of false positive signals from free dye is to process a dye-only control (without EVs) 
and observe the fluorescent intensity in the recipient cell [90]. In biodistribution studies, 
especially using lipophilic dyes, free dye can non-specifically bind to non-EV lipid structures 
leading to false positive signals. Additionally, since lipophilic dyes are estimated to have a 
longer half-life compared to EVs, they can remain in tissue even after the clearance of EVs 
[15,51]. In characterization studies of EVs using flow cytometry, unbound dye can contribute to 
the background signal and decrease the signal to noise ratio resulting in inaccurate analysis of 
EV samples [16,71,91]. Moreover, given the fact that the EV samples are not completely pure 
and contain proteins, protein aggregates and other contaminants, free dye can interact with 
these non-EV complexes and interfere with fluorescent labeled EVs. Therefore, in order to 
make a reliable conclusion in uptake, biodistribution and characterization studies of EVs by 
fluorescent labeling, a post-labeling step for removing the unbound fluorescent dye is required. 
Different techniques have been employed to separate labeled EVs from unincorporated dye 
including differential ultracentrifugation, density gradient centrifugation, size exclusion 
chromatography, and filtration.   
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1.3.3.1 Differential Ultracentrifugation:  
Ultracentrifugation has been widely used for isolation of EVs in biological fluids and cell culture 
conditioned media [20]. Using the same principle, It has been reported that labeled EVs can be 
separated from free dye by ultracentrifugation (~100,000 g and for at least an hour) [80,92]. 
The time of centrifugation is defined by properties of the rotor used and needs to be adjusted 
to achieve similar results between studies [93]. For example, removing of unbound dyes has 
been reported using differential ultracentrifugation from PKH26 labeled EVs at 100,000 g for 70 
minutes [80] and from DiO, DiR and FM labeled EVs at 120,000 g for 90 minutes [92]. 
1.3.3.2 Density Gradient Centrifugation:  
Similarly, density gradient centrifugation can be applied to separate labeled EVs from protein 
aggregates, free dyes and antibodies based on their buoyant density [20]. Density gradient 
technique requires 14 – 20 hours centrifugation at high forces (~ 200,000 g) to separate labeled 
EVs from free dyes [13,64,71,78]. Fluorescently labeled EVs equilibrate and can be collected at 
representative sucrose density of EVs (1.11 – 1.2 g/mL) without free dyes which have a lower 
buoyant density [64]. For instance, PKH67 labeled EVs have been successfully separated from 
free dyes and protein aggregates by overnight density gradient centrifugation at 270,000 g to 
demonstrate how non-EV particles in plasma can affect the fluorescent detection of EVs using 
high resolution flow cytometry [71]. DiR labeled EVs have also been purified from unbound 
dyes using sucrose gradient ultracentrifugation at 200,000 g for 16 hours [78].  
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1.3.3.3 Size Exclusion Chromatography:  
Size exclusion chromatography (SEC) is a powerful technique to enrich and isolate EVs from 
non-EV contaminates such as proteins and subsets of plasma lipoproteins based on size 
differences [20]. SEC has also been widely applied to remove free dye and unincorporated 
fluorophore conjugated antibodies from fluorescently labeled EVs [16,73,94,95]. For example, 
labeled EVs have been successfully separated from free Alexa Fluor 488 NHS [73] and DiR dyes 
[95] using SEC packed with Sepharose CL-4B. Unbound CFSE dyes have been also removed using 
PD-10 columns to detect tumor derived EVs with nanoscale fluorescent based flow cytometry 
[16,96]. The authors reported a detectable background noise from CFSE-alone controls due to 
spontaneous hydrolysis of CFSE dye. However, after removal of free CFSE using SEC, they 
observed an increase in the signal to noise ratio of EVs labeled with CFSE [16]. 
1.3.3.4 Filtration:  
Filtration has been used for separation of different size particles including EVs [20,97]. Filtration 
combined with low speed centrifugation has been also used for removing free dye from labeled 
EVs [13,14,52,74]. For example, PKH67 labeled EV samples at 4000 g has been removed the 
excess PKH dye by centrifugation through 300 KDa Viva-spin filters to study the uptake of EVs 
derived from human saliva, plasma and breast milk by macrophage [14]. The free dyes have 
been also filtered from R18 and TAMRA-NHS labeled EVs using 300 KDa [52] and 100 KDa [74] 
ultrafiltration membranes, respectively. In another study, 0.2 µm centrifugal filters were used 
to remove unbound antibodies by centrifugation at 600 g for 2-5 minutes [65]. 
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Each of these techniques for removing unbound dye has their own advantages and 
disadvantages and few studies have paid attention to the efficiency and purity of these 
techniques. The differential ultracentrifugation has been reported not sufficient to remove free 
dye aggregates whereas a density gradient was found necessary to remove free dye and dye 
aggregates from PKH67 labeled EVs [64,85]. In another study, higher removal efficiency of 
unbound CFSE dyes using SEC was reported compared to differential and density gradient 
ultracentrifugation [16]. These post labeling techniques are usually time and sample 
consuming, expensive and can cause undesired variation in the EV samples such as aggregation 
[57], which can be problematic for biodistribution, uptake and characterization studies. 
Filtration is a relatively fast and low-cost technique for removing excess dye, but has a low yield 
especially since EVs that are smaller than the pore size of the membranes can be lost and dye 
and protein aggregates larger than EVs can be retained [65]. In summary, the efficiency and 




1.3.4 Pros and Cons of Fluorescent Labeling Approaches 
1.3.4.1 Surface Marker Labeling 
Affinity-based labeling is the only labeling technique that can be considered 100% specific to 
EVs expressing the protein of interest. Combing surface marker labeling with a generic label can 
be used to identify the marker expression level of EVs using flow cytometry. However, the 
fluorescent intensity due to surface marker labeling depends on (i) the expression level of the 
target proteins, (ii) the efficiency of the labeling process, (iii) the light source excitation strength 
and the fluorescent dye quantum yield [90,98,99]. Additionally, the effect of labeling surface 
proteins on the uptake of EVs needs to be investigated since surface proteins are involved in 
the internalization of EVs [50,66]. Also, the surface protein labeling is limited in biodistribution 
studies since they tend to have a lower signal compared to other labeling techniques [15]. One 
other challenge with protein labeling of EVs is that antibodies tend to aggregate, therefore, 
removal of these antibody aggregates is crucial before labeling EVs. Removal of antibody 
aggregates has been reported by centrifugation at 16,000 g for 2-20 minutes [57,85,100].  
1.3.4.2 Lipid Membrane Labeling:  
Membrane dyes can be considered as generic markers since all EVs are membrane-enclosed 
vesicles. Due to the number of incorporated dye molecules, lipid-labeled EVs are also relatively 
bright and stable with a simple labeling process. However, recent studies have shown that 
lipophilic dyes tend to form aggregation and micelle formation which are in the same size range 
as EVs and are indistinguishable from EVs and can result in false positive results. Membrane 
dyes are not specific to EVs, since they can also label lipoproteins or even debris. Also, a higher 
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signal from labeling cell-free culture medium (as a negative control) compared to PKH-labeled 
EVs has been reported [99]. Similarly, specificity of lipophilic dyes for labeling EVs and 
contaminant artifacts such as lipoproteins and free proteins has been evaluated by 
fractionating rat blood plasma or conditioned cell culture media using size exclusion 
chromatography (SEC) [90]. The authors reported the significant contribution of non-EV 
contaminants in uptake studies suggesting that lipophilic dyes are not specific to EVs and not 
ideal unless a completely pure population of EVs is labeled [90]. Non-specificity of lipophilic 
dyes can also result in labeling the target cells in uptake studies [2,15].  
One other challenge of lipophilic dyes is their long in vivo half-life (5-100 days for PKH and 4 
weeks for DiR) for biodistribution studies. The long half-life of lipophilic dyes results in the 
persistence of lipophilic dyes in tissues for long periods even after the clearance and 
degradation of EVs leading to inaccurate determination of EV fate [15,49,50,74]. The effect of 
lipophilic dyes on surface properties of EVs also needs to be explored which could lead to 
changes in EV internalization [66]. 
1.3.4.3 Luminal Labeling:  
As opposed to lipophilic dyes, luminal dyes like CFSE do not tend to aggregate and form 
micelles. Another luminal dye, Calcein, has been used to differentiate between intact EVs and 
membrane fragments or other debris using flow cytometry [100]. In order to do so, they used 
Triton 100-X and saponin to permeabilize EVs derived from human plasma, red blood cells and 
conditioned media of human aortic endothelial cells. The authors found that calcein AM does 
not label permeabilized/lysed EVs as opposed to PKH67 lipophilic labeling [100].  
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However, it is important to note that esterase activity in all subtypes of EVs needs to be 
explored to determine the typical efficiency to hydrolyze the markers within EVs. In fact, a 
study on different generic markers for labeling EVs from breast cancer cells using flow 
cytometry revealed low sensitivity of calcein AM which could be due to insufficient esterase 
activity or low brightness of the labeled EVs for the system used [91]. Additionally, the authors 
were not able to study CFSE due to the swarm detection and insufficient event rates even after 
removal of excess dye using size exclusion chromatography [91]. Moreover, another study 
found that CFSE dye might also label lipoproteins and lipoproteins-like particles in complex 
fluids and recommended a combination of CFSE with a surface marker of EVs to enhance the 




1.4 Thesis Outline and Research Objectives  
In this work, following aims were defined and achieved focusing on isolation and 
characterization of extracellular vesicles;  
1.4.1.1 Aim 1 – Tangential Flow for Analyte Capture of Extracellular Vesicles 
A novel microfluidic based method, termed as tangential flow for analyte capture (TFAC), was 
developed for purification of extracellular vesicles using ultrathin nanomembranes. EVs from 
undiluted plasma were successfully captured using nanoporous silicon nitride (NPN) 
membranes. The performance of ultrathin nanomembranes was compared with conventional 
thickness membranes in this technique. NPN membranes were found ideal for this technique 
with higher capturing and releasing efficiency compared to conventional thickness membranes 
such as polycarbonate membranes.  
1.4.1.2 Aim 2 – Systematic Evaluation of PKH labeling on Extracellular Vesicles Size by 
Nanoparticle Tracking Analysis 
In this aim, the effect of PKH labeling, as the most commonly used dye, on the size of 
extracellular vesicles was systematically evaluated using nanoparticle tracking analysis (NTA). A 
size shift towards larger particles was found after PKH labeling of EVs, which could affect their 
uptake and biodistribution efficiency and mechanism. As opposed to PKH labeling, the size of 
EVs was preserved suggesting that CFSE is a more reliable dye for labeling EVs without affecting 
their size.  
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1.4.1.3 Aim 3 – The efficacy of the Virus Counter 3100 for detection of EVs 
In the last aim, precise quantification and characterization of EVs was performed using the virus 
counter 3100. The performance of VC3100 was compared with NTA and VC3100 was found 
ideal for precise quantification of nanoparticles in heterogenous samples such as EVs. 
Furthermore, single EVs from six different sources were successfully quantified by VC3100 using 
CellMask Orange dye. Protein profiling of EVs by VC3100 was also shown using PE conjugated 
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Chapter 2  






Membranes have been used extensively for the purification and separation of biological 
species. A persistent challenge is the purification of species from concentrated feed solutions 
such as extracellular vesicles (EVs) from biological fluids. We investigated a new method to 
isolate micro- and nano-scale species termed tangential flow for analyte capture (TFAC), which 
is an extension of traditional tangential flow filtration (TFF). Initially, EV purification from 
plasma on ultrathin nanomembranes was compared between both normal flow filtration (NFF) 
and TFAC. NFF resulted in rapid formation of a protein cake which completely obscured any 
captured EVs and also prevented further transport across the membrane. On the other hand, 
TFAC showed capture of CD63 positive small EVs (sEVs) with minimal contamination. We 
explored the use of TFAC to capture target species over membrane pores, wash and then 
release in a physical process that does not rely upon affinity or chemical interactions. This 
process of TFAC was studied with model particles on both ultrathin nanomembranes and 
conventional thickness membranes (polycarbonate track-etch). Successful capture and release 
of model particles was observed using both membranes. Ultrathin nanomembranes showed 
higher efficiency of capture and release with significantly lower pressures indicating that 





Tangential flow filtration (TFF) is used extensively in bioprocessing [1]. In this method, a feed 
solution containing a species of interest flows tangentially over a selective membrane with 
some fraction of the flow also passing through the membrane. If the species of interest is to be 
retained behind the membrane, TFF can be used to remove impurities or to concentrate the 
species in the feed solution [2, 3]. If the volume lost through transmembrane flow is resupplied 
to the feed channel as fresh buffer (diafiltration), TFF can be used for buffer exchange [4, 5]. 
TFF can also be used to partially purify a species that emerges in the filtrate, although the 
product typically requires final purification by column or membrane chromatography [6-10]. 
The advantage of TFF over normal flow filtration (NFF) is that the tangential flow component 
disrupts the formation of a concentration polarization layer that builds as species are rejected 
by the membrane [11]. Without a tangential component, this polarization layer will eventually 
form a ‘cake’ layer on the membrane with its own separation properties and significantly 
reduced permeate flux [12]. With TFF filtration however, it is possible to identify conditions for 
which both the flux and transmembrane pressure (TMP) are steady with time [13]. Under these 
conditions filtration can, in principle, continue indefinitely.  
Our laboratories develop ultrathin porous membranes for a range of applications including 
separations [14-17]. Ultrathin membranes are best defined as materials with pores on the same 
order as, or larger than, the membrane thickness [18]. These have been made with a variety of 
materials including silicon, silicon-nitride, silicon dioxide, graphene, and graphene-oxide [19-
24]. We have recently demonstrated that the high permeability of ultrathin membranes causes 
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them to foul rapidly in NFF, with initial pore blockage events quickly followed by cake filtration 
[25]. We showed the same fouling phenomena occurs with both particle and protein solutes 
when used in NFF [25, 26].  
To extend the capacity of ultrathin membranes in separations, we have recently examined their 
performance in TFF. Working with undiluted serum and nanoporous silicon nitride (NPN) 
membranes, we made the surprising discovery, reported here for the first time, that 60 - 100 
nm extracellular vesicles (EVs), are captured in the pores of ultrathin membranes with little 
evidence of protein fouling [27]. Our discovery inspired a closer look at the mechanisms and 
potential utility of capturing nanoparticle-sized analytes from biofluids in the pores of ultrathin 
membranes. 
Extracellular vesicles (EVs) are secreted from tissue cells into all body fluids, and EVs that are < 
100 nm are typically, but not exclusively, exosomes. Exosomes contain the largest pool of 
extracellular RNA (exRNA) in biofluids, and are thus valued both for their diagnostic and 
therapeutic potential [28-33]. The conventional method for exosome purification is 
ultracentrifugation although many alternative strategies have been proposed, including TFF 
[34-37]. Out of respect for the careful criterion used to define exosomes, we will refer to < 100 
nm EVs as small EVs (sEVs) rather than exosomes [38].  
We propose a novel method for the extraction of nanoparticle species from biofluids which we 
call tangential flow for analyte capture (TFAC). In this method, sEVs and similarly-sized analytes 
are captured in the pores of an ultrathin membrane where they can be washed and released 
with additional flows. TFAC resembles bind/elute purification strategies although it 
distinguishes itself from affinity chromatography because the binding is purely physical. TFAC 
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does not require engineered surface chemistries for capture or chemical treatments for elution. 
The purpose of the current report is to demonstrate the basic principles of TFAC using model 
particles. We also test the hypothesis that ultrathin membranes are ideally suited for TFAC 





2.3 Materials and Methods 
Fabrication of NPN Membranes 
The fabrication steps for nanoporous silicon nitride nanomembranes (NPN) have been 
published previously [19]. Briefly, a silicon wafer is coated with a three layer stack of silicon 
nitride (SiN), amorphous silicon, and silicon dioxide. A porous nanocrystalline silicon (pnc-Si) 
layer is formed on top of SiN via rapid thermal annealing. The nanopores present in the pnc-Si 
are transferred into the SiN layer by reactive ion etching. In order to create the freestanding 
membranes, the back side of the silicon wafer is etched to the silicon nitride layer using 
ethylene diamine pyrocatechol.  
NPN Device Fabrication 
Polydimethylsiloxane (PDMS) sheets (Trelleborg Sealing Solutions Americas, Fort Wayne, IN) 
were used to create microfluidic devices. Custom ordered 100 μm and 300 μm thick restricted 
grade sheets were patterned using a Silhouette Cameo digital craft cutter (Silhouette America, 
Oren, UT) [39]. The patterned silicone sheets were assembled into layer stack devices by 
aligning the patterned layers. NPN membrane chips (300 μm thick) were sandwiched between 
stacked layers and the final device was clamped to seal it for flow. 
PCTE Device Fabrication 
As a representative of conventional thickness membranes, commercial polycarbonate track-
etch (PCTE) membranes with pore sizes of 8 μm and 80 nm were utilized (Sterlitech, WA, USA). 
In order to have a sealed system for track-etch membranes, the above described microfluidic 
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device was modified. Holes were drilled in polycarbonate slabs for accessing the bottom 
channel of the device, while the PDMS slabs were punched for flowing to the top channel. We 
used 100 μm and 300 μm thick patterned PDMS sheets for bottom and top channels, 
respectively. In order to prevent leaking in the system, the PCTE membranes covering the entire 
device were sandwiched between the top and bottom layers using a clamp. 
sEV CAPTURE FROM PLASMA 
Normal Flow Filtration: Small extracellular vesicle experiments were performed using purified 
human plasma (Equitech-Bio, Inc., Kerrville, TX). NFF experiments were performed using NPN 
chips with 50 nm thick freestanding membranes, with an average pore diameter of 50 nm and a 
porosity of 15% in a SepCon™ centrifuge cup (SiMPore Inc., Rochester, NY). A 500 μL sample of 
undiluted plasma was spun at 1500 x g through the membrane and the chip was extracted from 
the device. The chip was allowed to dry and was then imaged by scanning electron microscopy 
as described below. 
Tangential Flow for Analyte Capture: Nanoporous silicon nitride microfluidic devices were 
fabricated as described above. The NPN chip used had a 50 nm thick freestanding membrane 
with a 50 nm average pore diameter and a 15% porosity. 1 mL of plasma was passed tangential 
to the membrane surface at a rate of 10 μL/min using a syringe pump (Chemyx Fusion 200, 
Chemyx Inc., Stafford, TX), while fluid was actively pulled through the membrane at a rate of 2 
μL/min. After processing the full 1 mL volume, the device was unclamped and the chip 
extracted. Captured sEVs were labeled for CD63 (Abcam, Cambridge, MA) and imaged via 
scanning electron microscopy as outlined below. 
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Capture and Release of Nanoparticles 
Microscale Experiments: Flow experiments were performed using two Chemyx Fusion 200 
syringe pumps (Chemyx Inc., Stafford, TX). Micron scale experiments with 10 μm polystyrene 
green fluorescent particles (Thermo Scientific, USA) were conducted on 8 μm track-etch 
membranes. Capturing step was performed using a sample supply flow rate of 90 μL/min and 
an ultrafiltration/pulling rate of 10 μL/min. Captured particles were released by reversed flow 
of 10 μL/min through the membrane.  
Nanoscale Experiments: These experiments were conducted using 100 nm polystyrene green 
fluorescent particles (Thermo Scientific, USA) on PCTE or NPN membranes with 80 nm median 
pore size. Nanoparticles were captured by supply flow rate of 5 μL/min and the 
ultrafiltration/pulling flow rate of 2 μL/min. Input channel was then cleaned by rinsing buffer to 
wash away the floating particles under the same flow condition as the capturing step. Finally, 
captured particles were released by reversed flow of 2 μL/min through the membranes.  
Time-Lapse Video Microscopy  
Devices were illuminated with metal halide lamp source (LE6000 Leica) through DIC and FITC 
(488 nm Ex/525 nm Em) filter sets on a Leica DM16000 microscope (Leica Microsystems, 
Buffalo Grove, IL) using the 10X objective. Images were collected using MetaMorph software 
with a Rolera em- camera (QImaging, Surrey, BC Canada) for 50 ms exposure time for FITC and 
10 ms for DIC. The measuring and merging channel tool in NIH ImageJ were used for 
quantifying the average intensity values and making videos by merging DIC with FITC images, 
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respectively. Images were taken every minute for nanoscale experiments and every second for 
microscale experiments.  
Electron Microscopy 
After the completion of experiments, the PCTE and NPN membranes were imaged via electron 
microscopy. Samples were prepared for electron microscopy by first removing the membranes 
from the device and then allowing them to air dry. Samples were then mounted and sputter 
coated with ~3-10 nm of gold. Scanning electron micrographs were taken at an accelerating 
voltage of 10 kV using either a Hitachi S-4000 scanning electron microscope (SEM) or a Zeiss 




Figure 2.1 – Tangential Flow Analyte Capture (TFAC) Technique for Isolation of Particles.  
(A) Microfluidic devices are assembled through a layer stack process, in which channels and other 
featured are patterned into PDMS sheets. (B) These layers are then formed into the device through 
thermal bonding or stacking and clamping. (C) The sample is passed across the surface of the 
membrane and a transmembrane pressure generated by syringe pumps drives particle motion towards 
the membrane. Contaminating particles pass through pores or are swept downstream while the 
particles are retained on the membrane surface. (D) The cleaning buffer is then passed through the 
input channel under the same flow condition as the capturing step to wash the channel and membrane 
surfaces of any remaining contaminants. (E) The transmembrane pressure is then reversed, releasing 





2.4.1 Tangential Flow for Particle Capture 
The system and scheme for particle capture and release is shown in Figure 2.1. As in our prior 
work [40-43], we used layer-by-layer assembly (Figure 2.1-A) to construct microfluidic devices 
(Figure 2.1-B) with membranes separating top and bottom flow channels. The only difference is 
that we used a clamped system for both PCTE systems and NPN systems instead of a fully 
bonded devices. This enables the removal and inspection of PCTE membranes or NPN chips by 
SEM after use. Particle capture (Figure 2.1-C) was performed using two syringe pumps: a 
positive pressure pump providing a constant sample supply flow rate into the input channel of 
the device, and a negative pressure pump at the output channel exit side controlling a smaller, 
steady rate of ultrafiltration through the membrane. The difference between the supply and 
ultrafiltration rates exited the top channel as waste and provided the tangential flow needed to 
prevent fouling [11, 13]. The inlet port on the bottom channel was blocked for all experiments. 
After capture, non-adsorbed contaminants could be cleared by replacing the sample with a 
rinse buffer while maintaining the transmembrane pressure (Figure 2.1-D) and captured 




Figure 2.2 - Small Extracellular Vesicles (sEV) Captured from Undiluted Blood Plasma. 
(A) SEM images showing the thinness and high porosity of nanoporous silicon nitride (NPN). (B) In 
normal flow filtration (NFF) a protein cake of ~8 μm cake rapidly builds up on the membrane surface. 
(C) After capturing and cleaning steps of TFAC, small vesicles are captured on the membrane surface 
with minimum fouling. (D) Nanogold conjugated anti-CD63 antibody labels an EV captured in a pore 
multiple times, indicating it is likely a CD63 positive sEV. Note: the fragmented appearance of the 
surface results from the use of a limited amount of gold (3 nm) to avoid obscuring the gold label on 
the antibody (18 nm). By contrast 10 nm of gold was sputtered on the samples to avoid charging 





2.4.2 Small EV capture from Undiluted Serum 
The initial discovery of analyte capture occurred with experiments on undiluted serum (Figure 
2.2). The scanning electron microscopy (SEM) image of the membrane can be seen in Figure 
2.2-A. In these experiments, we showed that the filtration of undiluted serum is difficult in NFF 
(Figure 2.2-B), causing an 8 μm cake of serum protein and salts to foul the membrane and 
allowing the passage of only 10 μL of a 1 mL sample. However, upon passing the undiluted 
serum across the membrane in tangential flow, we observed a significant reduction in the 
protein build-up on the membrane, showing captured particles (Figure 2.2-C).  
Human plasma and serum contain different types of particles including EVs and lipoproteins. 
Lipoproteins and EVs cannot be distinguished only by their physical properties since their size 
and density closely overlap [44, 45]. However, further analysis of the captured particles with 
immunostaining showed that some of the particles were positive for CD63 which is a common 
sEV surface protein and is not expressed on lipoproteins (Figure 2.2-D). We did not attempt 
rinse or release steps with undiluted serum, instead we turned to the following experiments 




Figure 2.3 - Microfluidic Device for PCTE Membranes. 
2.4.3 Microporous Track-Etch Capture of Fluorescent Particles 
We first explored the particle capture phenomena at the microscale using microporous 
polycarbonate track-etched (mPCTE) membranes with 8 μm pores and 10 μm particles. The 
schematic of the microfluidic device for PCTE membranes can be found in Figure 2.3. 
Polycarbonate and PDMS slabs with holes were used to have access to the bottom and top 
channels respectively. Top and bottom channels were patterned into PDMS sheets, and PCTE 
membrane was sandwiched between the channels. In order to make sure that the system is 
sealed, a plus sign design for channels were used and the PCTE was covering the entire device. 
At this scale we were able to image individual particle capture events in fluorescence 
microscopy (Figure 2.4). Before flow (T0; Figure 2.4-B) there were no particles on the 
membrane. With a steady supply rate of 90 μL/min and ultrafiltration rate of 10 μL/min 
particles began to accumulate on the membrane, primarily drawn directly to the pores (see 
electron micrograph in Figure 2.4-C, bottom panel), and the fluorescence steadily increased 












immediate release of particles loosely held on the membrane and a distinct, sudden drop in 
fluorescence (light blue line Figure 2.4-A). Finally, the flow was reversed by switching the 
ultrafiltration pump to infusion mode, resulting in a directional shift for the bottom flow. The 
bottom flow rate was then increased to provide a high transmembrane pressure in an attempt 
to fully release the remaining particles, although a fraction remained irreversibly bound 
resulting in a residual fluorescence after the experiment T2 (Figure 2.4-D). Electron microscopy 
(Figure 2.4-D, bottom panel) shows that most of these particles were not associated with pores 






Figure 2.4 - Microscale Experiments with 10 μm Fluorescent Particles and 8 μm Median Pore Size 
Polycarbonate Track-etch (mPCTE) Membranes. 
(A) SEM images showing the thinness and high porosity of nanoporous silicon nitride (NPN). (B) In 
normal flow filtration (NFF) a protein cake of ~8 μm cake rapidly builds up on the membrane surface. 
(C) After capturing and cleaning steps of TFAC, small vesicles are captured on the membrane surface 
with minimum fouling. (D) Nanogold conjugated anti-CD63 antibody labels an EV captured in a pore 
multiple times, indicating it is likely a CD63 positive sEV. Note: the fragmented appearance of the 
surface results from the use of a limited amount of gold (3 nm) to avoid obscuring the gold label on 
the antibody (18 nm). By contrast 10 nm of gold was sputtered on the samples to avoid charging 
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MATLAB code was generated to count the number of micron particles being captured and 
released over time. All the images in the time lapse series were binarized and summed over 
time to create the residence time map as it can be seen in Figure 2.5. The color indicates the 
residence time of the particles on the membrane (where yellow indicates longer residence 
time). In order to ensure that floating particles were not counted as a captured particle, a 
threshold of 3 images was applied so that particles that were in the field of view for less than 3 
images were excluded (Figure 2.5-A). Then, the images were binarized to yellow for the 
captured particles and blue colors for the membrane (Figure 2.5-B). Number of particles was 
calculated by dividing the yellow colored area by the area of a single particle for every single 
image during the experiment (Figure 2.5-C). More than 90% of the particles captured were released 
(Figure 2.4-A and Figure 2.5-C) suggesting this method has promise for the purification of microscale 
particles. 
 
Figure 2.5 - Counting of 10 Micron Fluorescent Particles. 
(A) Residence time map, (B) Binarized residence time map, and (C) Number of fluorescent particles - 

































2.4.4  Nanoporous Track-Etch Capture of Fluorescent Nanoparticles 
Having demonstrated capture using modified tangential flow in a microscale system, 
experiments were performed to show capture and release at the nanoscale (Figure 2.6). Track-
etch membranes with 80 nm pores (nPCTE) were used to capture 100 nm fluorescent 
nanoparticles. Because of the significant increase in membrane resistance compared to mPCTE, 
flow rates of 5 μL/min (sample supply) and 2 μL/min (ultrafiltration) were now used for capture. 
This was followed by washing with clean buffer to remove any non-specifically bound particles 
before the releasing in a backwash step (5 μL/min backflow).  
During the capture phase of the experiments, the fluorescence intensity curves displayed 
similar behavior to the microscale experiments, with a steady increase throughout the capture 
period (Figure 2.6-A). Unlike the mPCTE experiments however, there was no observable loss of 
fluorescence after the release of transmembrane pressure at the end of the capture phase. A 
fraction of loosely-associated particles, either on the surface or in suspension above the surface 
(Figure 2.6-C), were removed with a wash step.  
During the capture phase of the experiments, the fluorescence intensity curves displayed 
similar behavior to the microscale experiments, with a steady increase throughout the capture 
period (Figure 2.6-A). Unlike the mPCTE experiments however, there was no observable loss of 
fluorescence after the release of transmembrane pressure at the end of the capture phase. A 
fraction of loosely-associated particles, either on the surface or in suspension above the surface 






Figure 2.6 - Nanoscale Experiments with 100 nm Fluorescent Particles and 80 nm Median Pore Size 
Polycarbonate Track-etch (nPCTE) Membranes. 
(A) Fluorescent intensity analysis (solid line) showing the gradual increasing and decreasing in the 
fluorescent signal during the capturing step and cleaning step, respectively, followed by a sharp drop 
as nanoparticles were released (the dash line shows the intensity change during the experiment in the 
absence of the transmembrane pressure). Scale bar on fluorescence image insets = 50 μm. (B, C and 



























No Transmembrane Pressure appliedTransmembrane Pressure appliedA
D
500 nm     
After Releasing (T3) 
500 nm     
Before Capturing (T0) B
Washing
500 nm     









SEM images after capturing-cleaning step suggested capturing of nanoparticles on the pores, 
inside the pore channels and on the surface of the membranes. In order to determine the 
capturing sites on the membranes, samples were gradually tilted and imaged as it can be seen 
in Figure 2.7. High magnification SEM image of 60⁰ tilted sample showed captured particles on 
the pores, inside the pores, and on the surface of the membranes due to the charge interaction 
(Figure 2.7). Flow reversal did not fully remove all the particles captured on the membrane as 
some were lodged deep within pores (Figure 2.6-D and Figure 2.7), but the system did return to 
within ~85% of the baseline fluorescence value. 
In order to assess the role of the applied transmembrane pressure on capturing, experiments 
were performed in the absence of active transmembrane pressure (dashed line, Figure 2.6-A). 
To achieve this, supply flow was performed as before, but the ultrafiltration pump was not used 
to generate active transmembrane flow. While the change in fluorescence intensity showed an 
increase in particles, the maximum measured intensity was only 50% of the system with active 






Figure 2.7 - Characterization of Nanoparticles Capturing Sites of nPC-TE Membranes Using SEM 
Images. 
Micrographs were taken at different stage positions to show different perspectives. (A) Top down 









2.4.5 Nanoporous Silicon Nanomembrane Capture of Fluorescent Nanoparticles 
Our original observations of EV capture from serum (Figure 2.2) were obtained with 100 nm 
thick nanoporous silicon-nitride (NPN) membranes [27]. It is important to note that PCTE 
membranes used are approximately 60 times thicker compared to ultrathin nanomembranes. 
Thus, our next set of studies replicated the experimental conditions used with nPCTE on NPN (5 
μL/min supply; 2 μL/min ultrafiltration) with similar pore sizes (80 nm median) and total 
number of pores actively filtering materials were of the same order (nPCTE = 4 x 107 
pores/mm2; NPN = 9.2 x 107 pores/mm2), which resulted in a slightly larger membrane area for 
the nPCTE membranes (4 mm2) compared to the NPN membranes (1.4 mm2). Therefore, 
membrane thickness and membrane surface chemistry are the key parametric differences 
between experiments on nPCTE vs. NPN.  
Similar set of experiments as nanoporous track etch membranes under the same operating 
condition was performed to evaluate capturing and releasing of 100 nm fluorescent 
nanoparticles using NPN membranes (Figure 2.8). The capture and release intensity curves 
(Figure 2.8-A) with NPN show similar trends to nPCTE with some interesting differences. There 
is again an increase in fluorescence intensity on the membrane during the capture phase 
followed by a sudden loss of particles when the flows are stopped. After a rinse with clean 
buffer, the intensity returns to within ~95% of the baseline, which is slightly better than that 
seen with nPCTE (Figure 2.8-A, inset). A control in the absence of transmembrane pressure 





Figure 2.8 - Nanoscale Experiments with 100 nm Fluorescent Particles and 80 nm Median Pore Size 
NPN membranes. 
(A) Fluorescent intensity analysis (solid line) showing the gradual increasing and decreasing in the 
fluorescent signal during the capturing step and cleaning step, respectively, followed by a sharp drop 
as nanoparticles were released (the dash line shows the intensity change during the experiment in the 
absence of the transmembrane pressure). Scale bar on fluorescence image insets = 50 μm. (B, C and 
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Electron microscopy was again performed to better understand the capture process. The 
membrane showed high pore density (Figure 2.8-B), in contrast with track-etch membranes 
(Figure 2.8-B), and a distribution of pore sizes with median of 80 nm (Figure 2.9). As expected, 
the majority of the 100 nm particles captured remained on top of the pores (Figure 2.8-C). A 
small proportion of particles persisted on the membrane after the releasing step, and these all 
appeared to be captured within pores (Figure 2.8-D). 
In order to estimate particle concentrations throughout the capture and release process, 
calibration curves for both NPN and nPCTE experiments were made by correlating the 
fluorescent intensity to the number of particles on the membrane (Figure 2.10). 
 
Figure 2.9 - Pore Size Distribution for Nanoporous Silicon Nitride Membrane Chips. 
The pore distribution of NPN chips is heterogeneous, but the median diameter is 80 nm. The etching 
process produces random, large pores, but these would improve the capture of a heterogeneous 




Calibration curves for both PCTE and NPN membranes were obtained by correlating the 
fluorescent intensity with the number of fluorescent particles dried on the membrane. In order 
to avoid a coffee-ring effect during the drying process, water drops containing 100 nm 
monodispersed particles were dried on PCTE and NPN membranes at 80°C [46]. Drying the drop 
at higher degrees allowed the particles to accumulate at the air-liquid interface rather than at 
the drop edge leading to uniform deposition of particles [47].  
 
Figure 2.10 - Calibration Curves Correlating the Fluorescent Intensity to the Number of Particles on 
TE and NPN Membranes.  
(A) SEM image of a uniform deposition of fluorescent nanoparticles, (B) Binarized image, (C) TE 


























































The dried membranes were then placed back into the microfluidic devices and the channels 
were primed. Fluorescent images were taken using the Leica microscope and the intensity 
values were measured using ImageJ. Scanning electron microscopy was used to count the 
number of particles on the surface of the membranes. SEM images were binarized to black and 
white using ImageJ and number of particles in binarized SEM images was calculated by dividing 
the total area of particles by the area of a single particle. The best linear fit and the equation 
correlating the concentration of particles and the fluorescent signal were obtained and further 
used for analyzing the experimental data on PCTE and NPN. 
These curves allowed for the direct comparison of membrane performance for particle capture 
and release (Table 2-1). We estimate that track-etch membranes capture ~2.6 x 106 particles 
from an available population of 5 x 107 and released 60% of the particles captured. By contrast, 
silicon nanomembranes captured ~8.6 x 106 particles from the same solution and released 68% 
of the captured population. 
These curves allowed for the direct comparison of membrane performance for particle capture 
and release (Table 2-1). We estimate that track-etch membranes capture ~2.6 x 106 particles 
from an available population of 5 x 107 and released 60% of the particles captured. By contrast, 
silicon nanomembranes captured ~8.6 x 106 particles from the same solution and released 68% 
of the captured population. 





2.4.6 Pressure Modeling of Track-Etch and Ultrathin Silicon Nitride 
Nanomembranes 
We explored the effect of the membrane thickness on transmembrane pressure in our studies 
both analytically and experimentally. Experiments were conducted with nanoporous track-etch 
membranes and ultrathin nanoporous silicon nitride nanomembranes (Figure 2.11). Pressure 
sensors were placed upstream and downstream on either side of the membrane (Figure 2.11-A) 
and the pressures were monitored under flow conditions equivalent to the capture 
experiments (5 μL/min supply, 2 μL/min ultrafiltration). Results for both nPCTE and NPN 
compared favorably to predictions of the Dagan equation – a modified Hagen-Poiseuille 
equation that also applies to ultrathin membranes.[14, 41, 48] The Dagan equation gives the 









where 𝜇 is the fluid viscosity [Pa s-1], 𝑟 is the pore radius [m], and 𝐿 is the pore length [m]. The 
total membrane resistance 𝑅 is calculated by adding the resistance for each pore in the 
membrane in parallel (9.2 x 107 pores for NPN and 4 x 107 pores for nPCTE) and the anticipated 
pressure drop is then found by multiplying by the flow rate: 
 ∆𝑃 = 𝑄 ∙ 𝑅 (2.2) 
The comparison of this estimate with experimental results (Figure 2.11-B) showed that a simple 
analytical approximation is sufficient for predicting the transmembrane pressure drop that 
could be experienced in the system. These results were compared to an analytical model of 
 57 
 
pressure drop (Figure 2.11-B) as well as COMSOL Multiphysics simulations (Figure 2.11-C and 
2.11-D) to illustrate the pressure gradients and streamlines in the system. 
 
Figure 2.11 - Theoretical and Experimental Pressure Drops Across Nanoporous Polycarbonate Track-
etch Membranes (nPCTE) and Nanoporous Silicon Nitride (NPN) Membranes.  
(A) Diagram of the pressure monitoring system showing the position of the pressure sensors and the 
direction of flow. All flow was performed at 10 μL/min through the membrane with a syringe pump 
pushing on the top channel and a syringe pump pulling on the bottom channel. The pressure sensors 
were positioned 5 cm above and below the membrane. (B) Comparison of pressure drops across the 
track-etch and NPN membranes. Blue = Dagan predicted, homogeneous distribution pressure drop. 
Red =  experimental data. Logarithmic scale used for comparison.  (C) COMSOL model of pressure in a 
track-etch system showing a large pressure drop across the membrane. (D) COMSOL model of 
pressure in an NPN system showing almost no pressure drop across the membrane, in stark contrast 
to the track etch system. COMSOL simulations were performed using the Free and Porous Flow 





2.5 Discussion  
In this work, we introduced a new method for sample purification in which particles are 
captured on the surface of a membrane in tangential flow, washed to remove contaminants, 
and then released in a controlled fashion where they can be further analyzed, concentrated or 
processed. 
We call this process tangential flow for analyte capture (TFAC) and while the process resembles 
bind and elute strategies found in column or membrane chromatography, it relies on physical 
interaction, rather than chemical affinity, for capture. Similarly, TFAC requires physical release 
through back-flow for elution, rather than chemically treatments to disassociate chemical 
bonds formed during capture. As the release of chemical bonds in affinity schemes can often be 
destructive and incomplete, there are clear advantages for physical capture and release. 
Proof of concept experiments using fluorescent particles on both PCTE and NPN membranes 
showed successful capture and release of particles. We have shown that NPN membranes 
outperform PCTE membranes for capture and release with polystyrene nanoparticles. Our 
analytical and experimental comparison showed that the greater thickness of PCTE compared 
to NPN caused higher transmembrane pressure. This high pressure drives nanoparticles into the 
membrane bulk where they disappear from view and are more difficult to recover (Figure 2.8). 
One potential application of TFAC utilizing ultrathin membranes as a microfluidic based 
technique would be isolation of extracellular vesicles. Studies have indicated that not only the 
RNA content of these vesicles, but also their protein varies by cell of origin as well as by the 
pathologic state of these cells [49-53]. This differential cell state specific and cellular origin-
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based content indicates that EVs could serve as biomarkers of disease. These biomarkers could 
be used for a range of clinical purposes including disease screening, predicting a priori disease 
responsiveness to treatment, and monitoring response to treatment. Currently, the “gold 
standard” method for isolating extracellular vesicles from biofluids is ultracentrifugation, which 
requires large volumes of biofluid (> 25 ml), long processing times, expensive instrumentation 
and trained technicians. Gel precipitation and size exclusion chromatography and have been 
developed that remove the need for ultracentrifugation and allow extracellular vesicle isolation 
in a benchtop centrifuge, but these methods suffer from low yield and/or contamination with 
co-precipitated proteins [54-58]. The high protein contamination from these methods prevents 
the use of EV proteins as biomarkers in addition to RNA. The result from our plasma isolation 
experiment by ultrathin nanomembranes showing capture of EVs with minimal contamination 
suggests promising potential of TFAC for isolation of EVs with high purity (Figure 2.12).  
 
Figure 2.12 - Tangential Flow for Analyte Capture (TFAC) Illustration Showing Capturing, Cleaning 




Additionally, the pore size of the ultrathin NPN membranes can be tuned to capture different 
subpopulations of EVs that vary in size [59, 60]. This includes microvesicles, exosomes and 
apoptotic bodies which are diagnostically informative [61]. In all cases, TFAC method eliminates 
the necessity of preprocessing biofluids which can be both time consuming, result in sample 
loss, and often requires specialized equipment reducing the utility of these particles in point of 
care diagnostic devices [62, 63]. 
Another potential application of TFAC would be a membrane-based ‘in situ’ analysis to detect 
EVs carrying cancer biomarkers among a larger population using the same membrane for 
capture, labeling, and imaging by fluorescence microscopy. TFAC using NPN membranes 
showed that captured particles were associated with membrane surface, rather than trapped in 
a bulk-matrix which means that the captured particles can be analyzed directly on the 
membrane. Furthermore, TFAC captured extracellular vesicles from whole plasma with minimal 
contamination (Figure 2.2) as opposed to rapidly formed cake on the membrane by NFF which 
increases the sensitivity and specify of EVs biomarker detection. Also, the excellent optical 
properties of ultrathin inorganic membranes like NPN, would also be key to enabling this 
application [64]. In comparison, track-etch membranes lack this optical transparency and as the 
current study indicates, trap EVs below the membrane surface, together precluding the ability 
to detect specific diagnostic markers directly in and on the EVs captured on the membranes 
[65]. 
The abundant presence of EVs and lipoproteins with similar physical characteristics such as size 
and density in blood makes it one of the most difficult body fluids to isolate EVs from [66]. Co-
purification of EVs and lipoproteins has been observed using other size based separation 
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methods such as size exclusion chromatography and density gradient ultracentrifugation [44, 
45]. Therefore, contamination of EVs with blood lipoproteins may occur using TFAC. However, 
affinity-based separation can be performed downstream to decrease the blood lipoproteins 
contaminants level when EV samples with high purity is desired [67, 68]. On the other hand, 
lipoproteins are not likely to be present in cell-conditioned media, especially when cells are 




2.6 Future Directions 
2.6.1 NPN Membranes 
TFAC is a novel technique for separation of nanoparticles such as EVs based on size using 
ultrathin nanomembranes. Here, we showed the feasibility of this technique for purification of 
EVs. The TFAC system can be further optimized for higher yield and purity. In order to do so, 
following ideas can be explored;  
2.6.1.1 Minimizing the non-specific adsorption  
The yield can be improved by minimizing the non-specific adsorption due to their interaction 
with the surface of membrane and device channels. The surface of the channels and the 
membrane can be coated prior to purification step by 1% pluronic (PEO-PPO-PEO-block 
copolymer) solution. The system can be rinsed and washed with PBS after 1 hour of incubation 
with pluronic solution. This can help to maximize the EV retrieval and increase the purification 
yield.  
2.6.1.2 EV sample recirculation 
No loss of nanoparticles was observed in the pore channels of NPN membranes and the 
membrane stayed intact after the releasing step. Therefore, the purification yield can be 
further improved by collecting the sample from the outlet and recirculating them again in the 
system. After releasing the captured nanoparticles, the collected sample from the device outlet 
can be pumped to the device again for capturing the nanoparticles that were not purified in the 
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first step. Therefore, recirculation can be explored to increase the yield, especially since both 
the device and the membrane stay intact.  
2.6.1.3 Modifying the operating condition and the device design 
The flow rates applied for the purification need to be further optimized for the best yield and 
purity. Different flow rate combinations for pushing tangentially and pulling across the 
membrane can be tested and the number of particles purified can be then measured by NTA. 
Furthermore, the geometry of the channels is an important factor in the resistance and the 
transmembrane pressure, similar to the flow rates. Decreasing the height of the channels can 
help to increase the sample volume that is experiencing the transmembrane pressure required 
for nanoparticles to interact with the pores and get captured.  
2.6.2 Nanopocket Membranes 
2.6.2.1 Size based separation of subpopulation of EVs 
Separation of subpopulations of EVs based on size has received a lot of attention recently. 
Different sizes of EVs have recently purified by different steps of differential ultracentrifugation. 
The authors categorized the EVs in three subpopulations; large EVs which were pelleted by low 
centrifugation speed (2,000 × g), medium EVs pelleted by medium centrifugation speed (10,000 
× g), and small EVs which were recovered after high centrifugation speed (100,000 × g). 
However, the NTA analysis of separated EVs showed an overlap in the size of different 
subpopulations of EVs.  
In our lab, we have developed a new approach for fabrication of nanomembranes with well-
controlled pore sizes using nanosphere lithography (NSL) [69]. NSL uses close-packing of 
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nanoparticles to pattern pores in an ultrathin membranes (Figure 2.13). We have shown 
fabrication of ultrathin nanomembranes with pores in the same size range as EVs which can be 
used for separation of nanoparticles and EVs. In short, self-assembly of polystyrene 
nanoparticles was achieved at a water/hexane interface. By extracting it as a constant speed, 
the self-assembled monolayer of polystyrene nanoparticles was then deposited on a substrate. 
Using O2 plasma treatment, the size of nanoparticles was reduced. A mask was created by a 
thin Al deposition before the nanoparticles are removed via sonication. The generated voids in 
the Al mask was used to etch the pores and the membranes were then released from the silicon 
wafer substrate [69]. 
 
Figure 2.13 - Nanosphere Lithography (NSL) Process for Fabrication of Ultrathin Nanomembranes 
[69].  
The NSL technique can be extended to fabricate a novel nanomembrane, termed as, 
nanopocket membranes. Nanopocket membranes are a novel type of membranes with pores 
fabricated as a bowl with a hole at the bottom (Figure 2.14). Parylene film is a great candidate 
due to its conformal deposition properties, low cost, the biocompatibility. The nanopocket 
membrane purification can be performed in a TFF mode with a slight transmembrane pressure 
Released membrane














to capture target nanoparticles in the nanopockets. After capturing the nanoparticles, they can 
be released and collected simply by reversing the transmembrane pressure.  
 
Figure 2.14 – Cross-section Schematic of a Nanopocket Membrane. 
The ideal operating condition in TFF can be defined by critical flux, such that below this value, 
the process can be operated without membrane fouling. Below the critical flux value, the shear 
force is enough to keep the surface of the membrane clean and prevents the cake formation or 
the protein build up. This leads to continuous filtration with a transmembrane pressure rise 
under the constant flux conditions. We have recently studied the critical flux behavior of 
ultrathin (NTN) and conventional thick polymeric (nPCTE) nanomembranes and found that 
ultrathin nature of NPN membranes could enable a higher critical flux that nPCTE under the 
same protein concentration and flow conditions [70]. This result suggests that protein rich 
biofluids can be processed in TFF mode under the low transmembrane pressure of NPN 
membranes without fouling. The critical flux behavior of nanopocket membranes can be 
determined using a flux stepping technique and different concentrations of BSA solutions 
mimicking the protein concentration level of biological fluids. This can help to eliminate 




Furthermore, As a proof of concept, fluorescent nanoparticles with different sizes can be used 
to optimize the operation condition of the system like the applied flow rates for the highest 
purification yield and capturing efficiency. The concentration of fluorescent nanoparticles 
captured and released under different operation conditions can be determined by NTA.  
Nanopockets dimensions such as radius and depth can be tailored by adjusting the beads size 
and etching parameters, respectfully (Figure 2.14). Different nanopocket dimensions can be 
fabricated and used in TFAC system to separate subpopulations of EVs based on size. Purified 
EV samples can first be used to study feasibility of separation of subpopulations of EVs and the 
yield can be examined by NTA. The optimized operating condition for purification of EVs from 
different biofluids can be defined based on the results from fluorescent nanoparticles 
experiments for the highest yield, critical flux behavior of nanopocket membranes and 
separation of subpopulations of EVs from purified samples.  
2.6.2.2 Affinity based separation of subpopulation of EVs 
In addition to the size based, surface marker based separation of EVs have also received a lot of 
attention recently to identify the phenotype subsets of EVs. A recent study reported a 
microfluid based technique for single EV analysis to identify heterogenous biomarker profiles of 
EVs. The EVs were first immobilized inside a microfluidic chamber and then on-chip immuno-
staining and imaging were performed [71].  
As another future direction for TFAC system using nanopocket membranes, nanopocket 
membranes can be coated by specific ligands that selectively bind to EVs expressing the target 
protein marker. This can help to capture a specific subset of EVs which is beneficial for 




In this work, we have developed a method called tangential flow for analyte capture (TFAC) to 
capture and release of particles. We contend that ultrathin membranes are ideally suited for 
TFAC for two reasons: 1) operating pressures are orders-of-magnitude lower for ultrathin 
membranes than for membranes with conventional thicknesses (1-10 μm) and 2) captured 
particles are associated with a surface, rather than trapped in a bulk-matrix and 3) higher 
efficiency of capture and release of particles. Experiments performed in normal flow filtration 
with human plasma demonstrated formation of a protein cake on the surface of ultrathin 
membranes. However, testing human plasma in TFAC mode resulted in capturing extracellular 
vesicles with minimal contamination. Captured vesicles were further labeled in situ, providing a 
convenient platform for downstream detection and analysis. Together, these findings suggest 
promising potential of TFAC for both isolation of EVs and biomarker detection on captured EVs. 
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3 Systematic Evaluation of PKH Labeling of 






Extracellular vesicles (EVs) are membrane vesicles secreted by cells and can modulate biological 
activities by transferring their content following uptake into recipient cells. Labeling of EVs is a 
commonly used technique for understanding their cellular targeting and biodistribution. A 
reliable fluorescent technique needs to preserve the size of EVs since changes in size may alter 
their uptake and biodistribution. Lipophilic fluorescent dye molecules such as the PKH family 
have been widely used for EV Labeling. Here, the effect of PKH Labeling on the size of EVs was 
systematically evaluated using nanoparticle tracking analysis (NTA), which is a widely used 
technique for determining the size and concentration of nanoparticles. NTA analysis showed a 
size increase in all the PKH Labeling conditions tested. As opposed to lipophilic dye molecules, 
no significant shift in the size of Labeled EVs was detected with luminal binding dye molecules 
such as CFSE. This finding suggests that PKH Labeling may not be a reliable technique for the 





EVs are small membrane bound vesicles (50-1000 nm in diameter) secreted by all cell types 
examined and can be found in almost all biofluids including blood, breast milk, urine and saliva 
as well as in cell culture media [1,2]. EVs mediate cell-cell communication by exchanging 
proteins, DNA, RNA and lipids between donor and recipient cells and activating signaling 
pathways in target cells via receptor ligand interaction [3,4]. They have been shown to play a 
role in regulating both physiological and pathological processes including immune regulation 
and cancer [5].  
Studies that examine EVs uptake into target cells and in vivo biodistribution have utilized a 
range of Labeling and tracking approaches to follow EVs fate [6]. The most common technique 
for studying EVs biodistribution and target cell interaction involves Labeling of EVs with 
fluorescent dye molecules. Many strategies have been developed for Labeling EVs such as 
staining their membranes using fluorescent lipid membrane dye molecules such as PKH26 [7,8], 
PKH67 [9,10], DiI [11], and DiD [12]. The PKH family has been widely used in the lipophilic class 
as they have a highly fluorescent polar head group and long aliphatic hydrocarbon tails which 
readily intercalate into any lipid structure leading to long-term dye retention and stable 
fluorescence [12,13]. Using fluorescent Labeling, EVs secreted by cells into the extracellular 
environment have been found to be internalized through different routes and mechanisms 
including fusion with the plasma membrane and a range of endocytic pathways such as 
receptor-mediated endocytosis, phagocytosis, lipid raft-dependent endocytosis and 
micropinocytosis [14–16]. Furthermore, the internalization of EVs has been shown with a wide 
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range of recipient cells such as dendritic cells [9], macrophages [17], dermal fibroblast [18], 
endothelial and myocardial cells [10]. 
Previous studies have shown that the fate of nanoparticles can be affected by the size, shape, 
surface chemistry and hydrophobicity of nanoparticles [19–22]. In particular, the size-
dependent uptake of nanoparticles composed of inorganic materials including those made of 
polystyrene [23] and silica [24] has been conclusively studied. Lower cellular uptake of 
nanoparticles has been consistently observed with increasing nanoparticle size, possibly due to 
the increased energy required to take up the larger nanoparticles [24–27]. Additionally, size 
impacts the biodistribution of nanoparticles in vivo. For instance, more rapid accumulation of 
larger nanoparticles was observed to take place in liver and spleen [28]. Large nanoparticles 
also tend to exhibit shorter circulation half-life, which may be due to the activation of the 
complement system and quick removal of large nanoparticles from blood [29]. Therefore, size 
of nanoparticles plays an important role in uptake, biodistribution and circulation half-life of 
nanoparticles.  
Since previous studies have shown that cells preferentially uptake smaller EVs [30], altering the 
size of EVs may also affect their uptake into target cells. Therefore, a reliable fluorescent dye 
must preserve native properties of EVs, such as size, after Labeling. Despite the importance of 
preserving the size of EVs for uptake and biodistribution studies, the effect of the widely used 
PKH dye on the size of EVs has never been systematically characterized. The objective of this 
study was to systematically evaluate the effect of PKH Labeling on the size of EVs using 
nanoparticle tracking analysis (NTA). NTA is a technique for measuring the size and 
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concentration of nanoparticles in real time based on tracking the light scattered from 
suspended nanoparticles undergoing Brownian motion [25,31,32].  
In the present work, the ratio of PKH dye molecules to EVs was systematically varied and the 
particles’ size distribution were measured using NTA. In all the Labeling conditions tested by 
NTA, EVs size mode increased after Labeling. The observed size shift may trigger abnormalities 
in their tissue distribution and cellular uptake in both in vivo and in vitro studies. In contrast to 
PKH Labeling, CFSE-Labeled EVs showed similar size distribution as unLabeled EVs indicating 




3.3 Materials and Methods 
EVs Labeling with lipophilic dye (PKH)  
Lyophilized urinary CD63, CD9, CD81 positive EVs (HansaBioMed, Estonia) were diluted in ultra-
pure water to a protein concentration of 100 µg/mL, following manufacturer instructions. Prior 
to staining, 1.2 µL of 1 mM PKH26 stock (Red Fluorescent Cell linker for General Cell 
Membrane, Sigma-Aldrich) was added to 300 µL of diluent C and incubated at 37° C for 15 
minutes. Then, 1 µL of EVs stock was added to PKH26 in diluent C, resulting in a sample with 
final concentrations of 0.3 µg/mL of EVs and 4 µM of PKH26. Other concentrations of EVs (4.5, 
1.5 and 0.03 µg/mL) and PKH (20 and 0.16 µM) were made following the same overall 
procedure in diluent C.  
EVs Labeling with luminal binding dye (CFSE)  
5-(and-6)-Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) stock was made following the 
manufacturer instructions (CellTrace™ CFSE Cell Proliferation Kit, Thermo Scientific Fisher) by 
adding 18 µL of dimethyl sulfoxide (DMSO, Sigma-Aldrich) to the CFSE dye resulting in a 5 mM 
stock. In order to stain EVs with CFSE, 1 µL of CFSE stock was added to 300 µL of PBS prior to 
staining and then 1 µL of EVs from 0.1 µg/mL EVs stock was added and incubated for 2 hours at 
37° C, as was previously described [33]. In order to remove unbound dye molecules, the 
samples were ultracentrifuged (Optima MAX-XP, Beckman Coulter) at 100000 x g for 60 




Nanoparticle tracking analysis (NTA) 
For each run, 300 µL of the prepared samples were injected into the sample chamber of a 
NS300 instrument (NanoSight, Aumesbery, UK) with a 532 nm green laser. Seven 
measurements of each sample were performed for 30 seconds each. For the “Blur”, “Minimum 
expected particle size”, and “Minimal track lengths” the auto adjustment settings provided by 
software developer were used. The camera level (9-12) and detection threshold (2-6) were 
adjusted manually for each experiment as recommended by the manufacturer. For data 
capturing and analysis, the NTA analytical software (NanoSight NTA 3.2) was used. Briefly, from 
the recorded video, the mean square displacement of each detected particle was determined. 
Then, using the Stokes-Einstein equation, the diffusion coefficient and sphere-equivalent 
hydrodynamic radius were determined by the software.   
Fluorescent imaging and analysis  
Fluorescent images were taken using a Keyence BZ-X700 microscope (Keyence Corp. of 
America, MA, USA) with the same exposure time for all samples. The line scan analysis was 





3.4.1 Size Characterization of PKH Labeling of EVs 
In order to investigate the effect of PKH Labeling on the size of EVs, the particles’ size 
distribution was assessed by NTA (Figure 3.1). A heterogenous population of nanoparticles with 
a typical size range of small EVs (80 – 300 nm) was found in the EVs only control. Moreover, the 
PKH only control (without EVs) contained PKH nanoparticles, possibly micelles and aggregation, 
with a polydisperse particles’ distribution in the size range of 80 – 400 nm (Figure 3.1-A and B), 
which is in agreement with previously reported results [33,34]. Furthermore, after Labeling EVs 
with PKH, larger particles than those found in either the EVs or PKH only controls were detected 
by NTA (Figure 3.1-A and B), suggesting a size shift towards larger particles after PKH Labeling. 
In order to confirm that PKH is the reason for the observed size shift after Labeling EVs, the 
interaction of 100 nm polystyrene (PS) nanoparticles with PKH was studied as a control 
experiment. In contrast to EVs, PKH should not interact with PS nanoparticles and as expected, 
no size shift towards larger particles was observed by NTA when 100 nm PS nanoparticles were 
added to PKH (Figure 3.1-C). Therefore, Labeling EVs with PKH caused a size shift towards larger 





Figure 3.1 - Size Characterization of PKH Labeling of EVs by Nanoparticle Tracking Analysis (NTA). 
(A) NTA video frames of 0.3 µg/mL EVs only as control (EVs), 4 µM PKH only as control (PKH), and 
PKH-Labeled EVs (PKH+EVs) in diluent C. (B) Size distribution of EVs only control (EVs), PKH only 
control (PKH), and PKH-Labeled EVs (PKH+EVs) samples (n=7) in diluent C. (C) Size distribution of PS 














































3.4.2 Determination of the Fluorescent Detection Range of PKH-labeled EVs 
The fluorescent detection range of PKH-Labeled EVs samples was determined. PKH to EVs ratios 
were adjusted by changing the concentration of PKH while holding the EVs concentration 
constant (Figure 3.2). The fluorescent level of these samples along with that of the PKH and EVs 
only, as well as background only control groups were visualized using fluorescent microscopy 
and quantified by sampling the cross-sectional fluorescent intensity of the captured images 
(line scan). 
Initially, the same concentrations of PKH and EVs were used as in Figure 3.1. Weakly 
fluorescent features consistent with the presence of PKH nanoparticles in the PKH only control 
were observed by fluorescent imaging (Figure 3.2-A). In comparison to the PKH only control, 
several brighter features were observed in PKH Labeled EVs which are likely the larger particles 
formed after PKH Labeling of EVs (Figure 3.2-B). The line scan taken from the PKH-Labeled EVs 
showed higher fluorescent intensity compared to the background signal (Figure 3.2-E). Line 
scan analysis of the PKH-Labeled EVs revealed a reduction in the baseline signal when 
compared to the PKH only control; possibly as the result of floating PKH dye molecules 
interacting with EVs (Figure 3.2-E). Furthermore, intensity spikes found in the PKH-Labeled EVs 
further support the presence of larger Labeled EVs (Figure 3.2-E). In contrast, a 25-fold 
reduction of the PKH concentration (0.16 µM) led to a decrease in the fluorescent intensity that 
reached background level. This PKH reduction also caused the fluorescently bright features, 




Figure 3.2 - Determination of the Fluorescent Detection Range. 
Fluorescent images of (A) 4 µM PKH only control, (B) 4 µM PKH-Labeled EVs (1.5 µg/mL), (C) 0.16 µM 
PKH only control, (D) 0.16 µM PKH-Labeled EVs (0.3 µg/mL) in diluent C. (E) Representative line scan 
analysis of fluorescent images (A-D). Inset shows the line scan analysis of background, 0.16 µM PKH 
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3.4.3 Effect of PKH Concentration on the Size Distribution of PKH-labeled EVs 
Possible mechanisms causing the observed size increase are the aggregation/fusion of PKH 
nanoparticles with EVs or the intercalation of PKH molecules into EVs membranes, both of 
which would result in the formation of larger species. This suggests the possibility of minimizing 
the size increase by reducing the PKH concentration, while maintaining detectable fluorescent 
signal from PKH Labeled EVs. Therefore, after determining the fluorescent detection range of 
PKH-Labeled EVs, the effect of PKH concentration on the particles’ size distribution was 
explored by NTA (Figure 3.3). The concentration of PKH was systematically varied while holding 
EVs concentration constant. Representative examples of the particles’ size distribution 
measured by NTA for different concentrations of PKH can be seen in (Figure 3.3- [A-D]). For all 
concentrations of PKH, NTA analysis of particles’ size distributions showed that Labeling with 
PKH caused the formation of larger species relative to EVs and PKH only controls. Quantitative 
determination of NTA results was done by comparing the modes of the nanoparticle sizes 
(Figure 3.3-E). Consistent with size distribution results, a shift in the modes towards larger 
particles was observed in all PKH-Labeled EVs (PKH+EVs) compared to the EVs only control. 
Furthermore, no size shift was observed when the suspension buffer (diluent C) was added to 
EVs in the absence of PKH confirming that PKH is the cause for the size shift observed (Figure 
3.3-D). Therefore, Labeling EVs with different concentrations of PKH, even for the PKH 
concentration below the fluorescent detection limit, showed a size distribution shift indicative 
of the generation of larger species. This finding suggests that minimizing the formation of larger 
species by reducing the concentration of PKH used for Labeling EVs while maintaining the 




Figure 3.3 - Effect of PKH Concentration on the Size Distribution of Particles in PKH-Labeled EVs by 
Nanoparticle Tracking Analysis (NTA). 
(A-D) Size distribution of PKH-Labeled EVs with different PKH concentrations (20, 4, 0.16 and 0 µM 
respectively) with 0.3 µg/mL of EVs (n=7) in diluent C. (E) Particle size modes for EVs only control, PKH 
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3.4.4 Effect of EVs Concentration on the Size Distribution of PKH-labeled EVs 
Further confirmation of PKH induced larger species was done by varying the concentration of 
EVs while holding the PKH concentration constant (Figure 3.4). The PKH concentration (0.16 
µM) used was the level shown to generate fluorescently detectable PKH-Labeled EVs (Figure 
3.2-B). Representative examples of the particles’ size distribution measured by NTA for 
different concentration of EVs Labeled with PKH dye molecules can be seen in Figure 3.4-[A-D]. 
Additionally, quantitative determination of NTA results was conducted by comparing the size 
modes of the nanoparticles (Figure 3.4-E). As expected, generation of larger species was 
observed by size distribution as well as the shift in the size mode regardless of the EVs 





Figure 3.4 - Effect of EVs Concentration on the Size Distribution of Particles in PKH-Labeled EVs 
Evaluated by Nanoparticle Tracking Analysis (NTA). 
(A-D) Size distribution of PKH-Labeled EVs with different EVs concentrations (0.03, 0.3, 1.5, 4.5 µg/mL 
respectively) with 4 µM of PKH (n=7) in diluent C. (E) Particle Size modes of EVs only control, PKH only 
controls, and PKH-Labeled EVs (Error bars represent 95% confidence interval of the mean) in diluent 
C. 
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3.4.5 Size Characterization of CFSE labeling of EVs 
As opposed to lipophilic dye molecules which may cause a size shift towards larger particles, 
potentially through PKH nanoparticles fusion/aggregation or PKH dye molecules intercalation 
with EVs, it is anticipated that direct luminal Labeling of EVs with fluorescent compounds will 
not change the size of EVs. In order to study this hypothesis, EVs were Labeled with the CFSE 
luminal binding dye using a previously established protocol (Figure 3.5) [33]. Compared to the 
EVs only control and CFSE dye control (Figure 3.5-A), several brighter features were found in 
their fluorescent images (CFSE dye + EVs) which are likely the CFSE-Labeled EVs (Figure 3.5-B). 
Additionally, the line scan obtained from the CFSE-Labeled EVs showed intensity spikes 
indicating the presence of CFSE-Labeled EVs (Figure 3.5-C). In contrast to PKH dye, NTA analysis 
showed that CFSE did not form nanoparticles in the CFSE only control (Figure 3.5-A and D), 
which was in agreement with the previously reported findings [33]. Size distribution and 
quantitative determination of the particle size modes measured by NTA showed no significant 
change in CFSE-Labeled EVs compared to unlabeled EVs (Figure 3.5-D and E). This result 
suggests that luminal Labeling by luminal binding dye (CFSE) preserve the size of EVs after 





Figure 3.5 - Size Characterization of CFSE Labeling of EVs by Nanoparticle Tracking Analysis (NTA). 
Fluorescent images of (A) 16 4 µM CFSE only control, (B) 4 µM CFSE-Labeled EVs (0.3 µg/mL) in PBS. 
(C) Representative line scan analysis of fluorescent images (A and B). (D) Size distribution of EVs only 
control, CFSE only control, and CFSE-Labeled EVs (n=7) in PBS. (E) Size mode of EVs only control, CFSE 
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3.5 Discussion  
All cell types are capable of shedding membrane-enclosed vesicles called EVs that play a key 
role in intercellular communication. EVs have been found in diverse bodily fluids including 
blood, urine, saliva, amniotic fluids, ascites, cerebrospinal fluid and breast milk [2,35]. The use 
of extracellular vesicles for diagnostic and therapeutic applications has seen a major interest 
increase in recent years because of their capability to exchange components such as nucleic 
acids, lipids and proteins between cells [36]. Endocytosis and plasma fusion are considered as 
the main pathways for EVs internalization resulting in transferring EVs cargo to the recipient cell 
[15].  
To investigate the fate of EVs, many imaging tools and Labeling methods have been developed. 
Electron and optical microscopy are the most commonly used techniques for visualizing EVs 
[37]. However, due to the small size of EVs, their tracking can be challenging and they need to 
be fluorescently Labeled in their native state. Lipophilic Labeling with dye molecules such as the 
PKH family have been widely used to label a range of cell types such as mesenchymal stem cells 
[38,39] and tumor cells [40] in proliferation and migration studies [39,41]. Since EVs have a lipid 
bilayer structure similar to that of the cells plasma membrane, the PKH family has been 
adapted for EV Labeling due to the hydrophobic interactions between the EV lipids and the long 
alkane tails of PKH. Internalization of PKH-Labeled EVs by dendric cells [9], macrophages [17], 
endothelial cells [8] and fibroblasts [8] has been reported.  
Using polymeric, organic and inorganic nanoparticles, it has been shown that size, shape, 
surface chemistry and hydrophobicity of nanoparticles are important factors in their uptake and 
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biodistribution [19–22]. The effect of nanoparticle size alone on their uptake has been 
investigated using different types of nanoparticles and cells such as mesoporous silica 
nanoparticles on HeLa cells by [28], fluorescent latex beads on B16 cells [42], as well as 
polystyrene nanoparticles on Caco-2 and MDCK cells [23]. In addition to cellular uptake 
efficiency, It has been shown that nanoparticles smaller than 200 nm can be taken up by 
clathrin-coated pits, while larger particles tend to be internalized by caveolae-mediated 
processes [42]. In addition to uptake studies, the biodistribution of intravenously injected 
polystyrene nanoparticles has been reported in different organs of rats [23]. The authors found 
200 nm nanoparticles showed higher accumulation in both liver and spleen compared to 100 
nm nanoparticles. All taken together, these evidences suggest a size shift from 100 nm to 200 
nm decreases the cellular uptake efficiency and kinetics and affects their biodistribution. 
Although studies have recognized the importance of size of nanoparticles in uptake and 
biodistribution, the research has yet to systematically investigate the effect of fluorescent 
Labeling on the size of EVs. Importantly, fluorescent Labeling must preserve the size of EVs 
since any size change may alter the uptake and distribution of EVs.  
The size and concentration of nanoparticles including EVs have been determined using different 
techniques with their own advantages and limitations such as electron microscopy (SEM and 
TEM), atomic force microscopy (AFM), dynamic electron microscopy (DLS) and nanoparticle 
tracking analysis (NTA). NTA is a widely used technique in the field and is of particular interest 
in this study since it is quick to perform and it provides a detailed analysis of the measuring 
sample leading to statistically significant nanoparticles’ size distribution. Furthermore, NTA 
does not require processing procedures such as drying and coating which can affect the 
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nanoparticles properties [43–46]. Hence, the present study set out with the aim of assessing 
the impact of PKH Labeling on the size of EVs using NTA. The concentration of both PKH dye 
and EVs were systematically varied and the particles’ size distribution was determined by NTA. 
In all conditions tested, NTA analysis revealed a size mode shift from ~100 nm for unlabeled EVs 
to ~200 nm for PKH Labeled EVs. 
In agreement with our findings, one study used the lipophilic tracer dialkylcarbocyanine (DiI) to 
enhance clustering and aggregation of EVs which was confirmed by electron microscopy and 
flow cytometry [47]. Furthermore, It has been shown that another lipophilic dye, styryl dye 
(also referred to as FM™ dye), results in larger EVs after Labeling which was characterized by 
flow cytometry [48]. Additionally, different approaches for Labeling EVs has been evaluted by 
nanoscale flow cytometry [33]. The study’s main focus was to identify the method that 
generates fewer background contaminants during the Labeling process and not the effect of 
Labeling on EVs size. Their NTA data also showed a size shift towards larger particles after PKH 
Labeling of EVs, however this was not mentioned by the authors in the study [33]. Additionally 
the biodistribution of EVs using DiR (a similar lipophilic dye as PKH) has been examined and it 
was found that lipophilic Labeling of EVs increased the localization of EVs in liver and spleen 
[28]. This change in the biodistribution may be due to the increase in size of EVs after Labeling 
by lipophilic dye molecules. These previously reported results further support our findings 
regarding the size change of EVs after Labeling with lipophilic dye molecules such as the one 
belonging to the PKH family. In summary, the size shift towards larger particles caused by PKH 
Labeling of EVs is likely to change the cellular uptake level and internalization mechanism as 
well as the biodistribution of EVs, reducing its validity as an EVs tracer. 
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In addition to the concern regarding the size change of EVs after Labeling, recent studies have 
highlighted the generation of artifacts such as formation of numerous nanoparticles which 
consist exclusively of micelles/aggregates of PKH, without EV content [33,34,49]. It was further 
shown that in terms of size, surface area and fluorescent intensity, the PKH nanoparticles 
cannot be distinguished from PKH Labeled EVs and were taken up by astrocytes. Therefore, this 
capacity for cell uptake of PKH nanoparticles may lead to false positive signals in EV tracking 
studies [34]. However, cyanine-based membrane probes called MemBright have been recently 
developed which do not form nanoparticles which is essential for tracking EVs, in contrast to 
the commonly used PKH family [50,51]. Another lipophilic dye, CellMask orange, has been also 
used for labeling EVs without affecting the size of EVs, characterized by NTA [52]. 
One alternative to lipophilic dye molecules that stain the membrane of EVs, is luminal Labeling 
such as CFDA-SE. CFDA-SE dye molecules are membrane permeable chemical compounds that  
covalently bind to primary amine inside EVs and fluoresce after ester hydrolysis of the dye in 
the lumen of the EVs which forms active CFSE molecules [53–56]. Therefore, we hypothesized 
that luminal binding dye molecules do not affect the size of EVs. In order to study this 
hypothesis, the luminal binding dye CFSE was used to label EVs and the size of EVs was 
determined before and after Labeling with NTA. NTA results showed that as opposed to PKH 
Labeling of EVs which increased the size of EVs, CFSE dye Labeling maintained the normal size 
of EVs which precludes any size related cellular uptake and biodistribution aberrancies. 
Consistent with our finding, other studies have found luminal binding fluorescent compounds 




Here, NTA was employed to systematically explore the effect of PKH Labeling on the size of EVs 
by changing the PKH to EVs ratio. In all conditions tested, a size mode shift towards larger 
particles was observed after PKH Labeling of EVs which may cause aberrancies in cellular 
uptake, biodistribution and half-life circulation. This observed size shift combined with other 
previously reported artifacts such as formation of PKH nanoparticles suggest that the PKH 
family dye is not reliable for Labeling EVs. In contrast to the lipophilic class such as PKH, luminal 
binding dye molecules like CFSE did not cause a size shift in Labeled EVs, suggesting that CFSE 
may be a better Labeling option for EVs by preserving the size of EVs after Labeling. However, It 
is important to note that the effect of CFSE Labeling of EVs on their biological behavior such as 
their uptake and biodistribution needs to be further explored. Furthermore, CFSE is not the 
only alternative for lipophilic dye molecules such as PKH and suitability of other fluorescent 
Labeling methods needs to be investigated in future studies using different techniques such as 
NTA, flow cytometry and electron microscopy.  
One alternative to lipophilic dye molecules that stain the membrane of EVs, is luminal Labeling 
such as CFDA-SE. CFDA-SE dye molecules are membrane permeable chemical compounds that  
covalently bind to primary amine inside EVs and fluoresce after ester hydrolysis of the dye in 
the lumen of the EVs which forms active CFSE molecules [53–56]. Therefore, we hypothesized 
that luminal binding dye molecules do not affect the size of EVs. In order to study this 
hypothesis, the luminal binding dye CFSE was used to label EVs and the size of EVs was 
determined before and after Labeling with NTA. NTA results showed that as opposed to PKH 
Labeling of EVs which increased the size of EVs, CFSE dye Labeling maintained the normal size 
of EVs which precludes any size related cellular uptake and biodistribution aberrancies. 
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Consistent with our finding, other studies have found luminal binding fluorescent compounds 
did not form nanoparticles and did not increase EVs size after Labeling using flow cytometry 
[33,48] . 
 
Figure 3.6 – PKH Labeling of Extracellular Vesicles Results in a Size Shift Towards Larger Particles 
 
Here, NTA was employed to systematically explore the effect of PKH Labeling on the size of EVs 
by changing the PKH to EVs ratio. In all conditions tested, a size mode shift towards larger 
particles was observed after PKH Labeling of EVs which may cause aberrancies in cellular 
uptake, biodistribution and half-life circulation. This observed size shift combined with other 
previously reported artifacts such as formation of PKH nanoparticles suggest that the PKH 
family dye is not reliable for Labeling EVs (Figure 3.6) . In contrast to the lipophilic class such as 
PKH, luminal binding dye molecules like CFSE did not cause a size shift in Labeled EVs, 
suggesting that CFSE may be a better Labeling option for EVs by preserving the size of EVs after 
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Labeling. However, It is important to note that the effect of CFSE Labeling of EVs on their 
biological behavior such as their uptake and biodistribution needs to be further explored.  
It is important to note that CFSE is not the only alternative for lipophilic dye molecules such as 
PKH. The suitability of other fluorescent Labeling methods needs to be investigated in future 
studies using different techniques such as NTA, flow cytometry, and electron microscopy, and 
atomic force microscopy.    
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3.6 Future Directions 
Many new dyes have been recently developed to fluorescently label EVs. However, there is no 
ideal generic fluorescent dye in the field that can label all and only EVs. The ideal generic 
fluorescent dye stills needs to developed and should fulfill the following requirements;  
A. Labeling of all EVs: Labeling only a subpopulation of EVs can lead to inaccurate conclusions 
in uptake, biodistribution and characterization of EVs. Therefore, an ideal fluorescent dye must 
label all EVs.  
B. Specificity to EVs: Labeling non-EV contaminants in the samples can lead to false positive 
signals in EV studies. Therefore, a fluorescent dye with specificity to EVs is required for reliable 
characterizations and conclusions.   
C. Minimal Background Signal: Presence of excess dye and dye nanoparticles are important 
challenges in studying EVs which can result in inaccurate conclusions by contributing to the 
detected signal. An ideal dye must not fluoresce in the absence of EVs.  
D. High Signal-to-Noise: Brightness and stability of the dyes is an important factor in their 
detection, especially in flow cytometry analysis where a high signal to noise ratio is necessary 
with sufficient sensitivity to detect all EVs.  
E. Preserving the native biological behavior of EVs: Affecting the natural biological behavior of 
EVs can be problematic specially in uptake and biodistribution studies. An ideal dye must not 
modify the natural biological behavior of EVs.  
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F. Preserving the physical properties of EVs: An ideal fluorescent dye must preserve the 
physical properties of EVs such as size which can affect their behavior in uptake and 
biodistribution studies. 
3.6.1 Confirming the Size Shift of EVs After PKH Labeling by Tangential 
Techniques  
Here we explored the effect of PKH labeling on the size of EVs using NTA. To further confirm 
and understand the mechanism of the observed size shift, other techniques such as electron 
microscopy (EM) and atomic force microscopy (AFM) can provide valuable information. In order 
to do so, the size of EVs can be characterized by imaging before and after labeling using EM or 
AFM as a tangential technique with different principles than NTA .In addition to PKH labeling, 
the effect of fluorescent dyes on the size of EVs after labeling by other available and commonly 
used fluorescent dyes still needs to be systematically evaluated using NTA, AFM and EM.   
3.6.2 Studying the Biological Significance of the Observed Size Shift by PKH 
labeling 
Furthermore, we believe that the size shift can affect the uptake and biodistribution of EVs 
based on previous studies using different types of nanoparticles. However, the biological 
significance of the observed size shift on the uptake or biodistribution of EVs can be further 
explored to support this conclusion. This can be done by experimentally addressing the effect 





Lipophilic Labeling of EVs has been shown to have multiple drawbacks. First, non-specific 
labeling of non-EV biofluid components such as microvesicles, lipoprotein particles, and 
proteins [49]. Second, the in vivo biodistribution of EVs has been shown to be altered by 
lipophilic Labeling [23]. Third, the formation of PKH nanoparticles was observed which can 
potentially cause false positive results in EV cell uptake and biodistribution studies. Fourth, a 
size shift in the size of EVs was shown after labeling, most likely due to PKH nanoparticle 
fusion/aggregation and PKH dye intercalation with EVs. These larger species formed after PKH 
labeling of EVs may cause aberrancies in cellular uptake, biodistribution and half-life circulation.  
Here, the relative ratio of PKH to EVs was systematically studied in order to minimize the EV 
size shift towards larger particles by PKH Labeling while maintaining the fluorescent detection 
of Labeled EVs. In all conditions tested, formation of larger species after Labeling was detected, 
even in the conditions where the PKH level is below the fluorescent detection level. In contrast 
to lipophilic dyes such as PKH, protein binding dyes like CFSE did not cause a size shift in 
Labeled EVs, suggesting that CFSE may be a better Labeling option for EVs.  
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4 Quantification and Characterization of Extracellular 





Robust and well-established techniques for the quantification and characterization of 
extracellular vesicles (EVs) are a crucial need for their utilization as they emerge as a potential 
diagnostic and therapeutic. Current bulk analysis techniques such as proteomics and western 
blot suffer from low-resolution in the detection of small changes in target marker expression 
levels, exemplified by the heterogeneity of EVs. Microscopy-based techniques can provide 
valuable information from individual EVs; however, they are time consuming and statistically 
less powerful than other techniques. Flow cytometry has been successfully employed for the 
quantification and characterization of individual EVs within larger populations. However, 
traditional flow cytometry is not highly suited for the examination of smaller, sub-micron 
particles. Here we demonstrate accurate and precise quantification of nanoparticles such as 
EVs using the Virus Counter 3100 platform (VC3100), a fluorescence-based technique with 
similar principles as flow cytometry with critical enhancements to enable the effective 
detection of smaller particles. This approach can detect nanoparticles precisely with no 
evidence of inaccurate concentration measurement from masking effects associated with 
traditional nanoparticle tracking analysis (NTA). Fluorescently labeled EVs from different 
sources were successfully quantified using the VC3100 without a post-labeling washing step. 
Moreover, protein profiling and characterization of individual EVs was achieved and shown to 






Several studies have reported an elevated EV release when cells are subjected to stress, 
activation, stimulation, as well as disease states such as cardiovascular disease, cancer, sepsis, 
and auto-immune diseases compared to the healthy cells [1–3]. EVs in biological fluids have 
been proposed as novel biomarkers for noninvasive detection and monitoring of diseases 
[2,4,5]. Therefore, precise quantification and biomarker profiling of EVs are essential to enable 
their potential as diagnostic and therapeutic tools.  
EVs are highly heterogeneous with respect to size, cells of origin, composition, and surface 
protein expression [6–8]. Due to their small size and heterogeneity, quantitative and qualitative 
analysis of EVs remains challenging using bulk analysis techniques such as proteomics, 
lipidomics, and Western blot. For example, bulk analysis techniques are incapable of detecting 
small changes to target markers for example. Moreover, the detected differences in the target 
expression may be related to the number of EVs tested [6,9–12]. A preferred alternative would 
be the quantification and characterization of EVs on a single particle basis. Visualization based 
techniques such as electron microscopy (EM) and atomic force microscopy (AFM) have been 
used to characterize EVs [13–15]. However, these techniques are time-consuming and are not 
sufficiently statistically powerful [6,7,12]. Nanoparticle tracking analysis (NTA) is the most 
widely used technique for determining the size and concentration of EVs [16–18]. Nevertheless, 
NTA as a scattering based technique is less accurate and precise with heterogeneous sample 
populations such as EVs and is incapable of discriminating contaminants such as protein 
aggregates from true individual EVs [12,19–21]. In recent years, high-resolution flow cytometry 
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has been developed to detect nano-sized particles [10,11,22]. However, the scattering-based 
analysis by flow cytometry can lead to incorrect measurements due to the confounding issues 
of coincidence and swarm detection caused by the simultaneous presence of multiple EVs 
within the analysis window [10,21]. Additionally, the small size of EVs and their low refractive 
indices make their detection from the high background instrument noise challenging [12,20,23].  
Fluorescent-based detection of EVs using flow cytometry has been employed to better resolve 
EVs from the background noise and is independent of size and refractive index [5,24]. However, 
the unincorporated fluorescent dyes post labeling can contribute to the background noise and 
consequently adversely affect the signal to noise ratios [22,24,25]. Therefore, a sensitive, 
reliable, and high throughput technique is needed to precisely quantify and characterize EVs.  
The Virus Counter 3100 platform (VC3100) is a powerful, automated, and fluorescence-based 
technique originally developed explicitly for the quantification and characterization of viruses 
[26,27]. As viruses and extracellular vesicles share many common features, we were interested 
in determining if the VC3100 could be adapted to the study of EVs [28]. Here, we demonstrate 
that the VC3100 can be used for accurate quantification and biomarker profiling of EVs, where 
an assay does not require washing to remove unbound fluorescent reagents. We compare the 
performance of the VC3100 and NTA and find that the VC3100 is not prone to small particle 
masking by larger particles that we observe with NTA analysis. We further studied the effect of 
coincidence and swarm detection on the measured concentration to verify the analysis of 
individual nanoparticles. We also showed that EVs from different sources can be reliably 




4.3 Materials and Methods 
Virus Counter 3100   
VC3100 was purpose-built for the detection of viruses.  It uses the principle of hydrodynamic 
focusing to align particles in a narrow core for interrogation by laser light. The emitted light 
from fluorescent particles passing the laser spot is captured in photomultiplier tubes and time 
stamped (Figure 4.1). Unique design features that support nanoparticle detection include a 
sample flow rate that is orders of magnitude lower than what is used in conventional flow 
cytometry; a core stream that is half to a third of conventional instruments; and a laser that is 
an order of magnitude higher in power than conventional cytometry, all combined with other 
unique design features.  The detection limits of the VC3100 are 5×10& - 1×10'particles/mL.  
Virus Counter 3100 measurement of nanoparticles  
For each test, 300 µL of the prepared nanoparticles samples (ThermoFisher) were run through 
the flow cell of the VC3100 instrument equipped with a 532 nm laser line. Three independent 
replicates of each sample were tested (n=3) for 60 seconds each.  
Nanoparticle tracking analysis measurement of nanoparticles 
For each analysis run, 300 µL of the prepared samples were injected into the sample chamber 
of an NS300 instrument (NanoSight, Amesbury, UK) equipped with a 532 nm laser line. Three 
measurements of each sample were performed for 30 seconds each. Three independent 
replicates of each sample were tested (n=3). For the "Blur," "Minimum expected particle size," 
and "Minimal track lengths," the stock auto adjustment settings provided with the instrument 
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software were employed. The camera level (13) and detection threshold (5) were kept constant 
between measurements. For data capturing and analysis, the NTA analytical software 
(NanoSight NTA 3.2) was used.  
 
Figure 4.1 - Schematic Showing the Working Principle of the Virus Counter 3100.   
Serial dilution experiments 
3-fold serially diluted samples of 50, 100, and 200 nm polystyrene nanoparticles were prepared 
in the concentration range of 5×10( - 5×10' for NTA and 5×10& - 5×10'  for VC3100. For each 
sample, 3 independent replicates with a total volume of 300 µL were tested.   
 
 










Mixture of Nanoparticles experiments 
Stocks samples with the same concentrations of 50, 100, 200 nm polystyrene nanoparticles 
(ThermoFisher) were made. Different ratios of mixtures of nanoparticles were subsequently 
added together in PBS with the final concentration of 300 µL. For example, 50 µL of 50, 100, 
and 200 nm nanoparticles (same concentrations) were added to 150 µL PBS.   
Extracellular Vesicles Samples 
Lyophilized exosome standards from biofluids (plasma, serum, urine, and saliva) of healthy 
donors and exosomes derived from conditioned cell culture medium (HEK293 and mouse cell 
line B16F10), were used from HansaBioMed, Estonia. 1 mL of deionized water was added to 100 
µg lyophilized standard to a final protein concentration of 0.1 µg/µL. The exosome samples 
were then resuspended by repeated pipetting. The reconstituted standards were mixed by 
vortex for 60 seconds. Following a brief centrifugation step, the samples were then aliquoted 
into polypropylene vials and stored at -20° C for up to 6 months.  
CellMask Orange Labeling 
CellMask orange (CMO) plasma membrane stain (5 mg/mL) was purchased from ThermoFisher. 
The CMO stock was diluted 1000 times to a final concentration of 5 µg/mL. 10 µL of EVs from 
stock (2.5×10))) were added to 10 µL of 1000X diluted CMO (5 µg/mL) and were incubated for 






Detergent Treatment Experiment 
5 µL of CMO dye (1000X or 5 µg/mL) was added to 10 µL of EVs (5×10') from different sources 
of EVs. After 30 minutes of incubation at room temperature, 85 µL of PBS was added. 45 µL of 
CMO labeled EVs were treated with 5 µL of 10% Triton-X100 or PBS as the untreated control for 
on ice. After an hour of incubation on ice, 5 µL of the untreated and detergent treated samples 
were added to 195 µL of PBS and then measured by the VC3100.  
Immunofluorescent labeling of EVs 
PE-conjugated CD9 (Clone MEM-61), PE-conjugated CD63 (Clone H5C6), PE-conjugated CD81 
(Clone JS-81), and PE-conjugated mouse IgG1, k (Clone MG1) were all purchased (Novus 
Biologicals, Littleton, Co). 5 µL of 50 µg/mL PE-conjugated antibodies against CD9, CD63, CD81 
and the isotype control were added to 10 µL of EVs (2×10)*). The mixture was incubated for 2 
hours at 37 °C and was diluted 100 times prior to the analysis on the VC3100. 
Statistical Analysis 
GraphPad Prism version 8.0 (GraphPad software) was used for all statistical analyses. Paired 
two-tailed Student’s t-tests were performed to determine the significance of the differences in 






4.4.1 Performance of VC3100 in the Detection of Polystyrene Nanoparticles 
A guideline was recently published as a framework for standardized reporting of extracellular 
vesicles flow cytometry experiments [29]. As recommended by the guideline, serial dilution of 
the samples is a requisite assay controls to establish individual nanoparticles detection on an 
instrument. Serial dilutions of 200, 100 and 50 nm polystyrene (PS) nanoparticles were 
measured in the VC3100. The serial dilution plots of PS nanoparticles could be defined by three 
regions (Figure 4.2); a) The linear region; The nanoparticles samples maintained a linear count 
consistent with the dilution factor indicating the detection of single PS nanoparticles by the 
VC3100 in this region. b) The coincidence region; The nanoparticles counts were no longer 
linear in relation to the dilution factor anymore and reached a plateau. In this region, two or 
more nanoparticle were present in front of the laser and were counted as one event leading to 
an underestimation of the sample’s concentrations. c) The swarm region; The samples 
concentrations were high enough such that a large number of particles entered the laser spot 
simultaneously. As a result, the baseline values failed to restore to the PBS to control levels. 
This resulted in consistently elevated baseline values. At high sample concentrations, the core 
stream was saturated with nanoparticles, leading to a reduction in the measured concentration 
by the VC3100. These results demonstrate that the VC3100 is capable of individual 
nanoparticles detection from both the ability to demonstrate a linear correlation with dilution 




Figure 4.2 - Serial Dilution of 50, 100, 200 nm Polystyrene (PS) Nanoparticle to Evaluate the 
Performance of VC3100 in the Linear and Saturable Enumeration of Individual Nanoparticles. 
 
4.4.2 Performance Evaluation of NTA and VC3100 for Accurate Quantification of 
Nanoparticles in Polydisperse Samples 
Nanoparticle Tracking Analysis (NTA) is the most widely used technique in the extracellular 
vesicles (EVs) field for enumeration and sizing of nanoparticles in suspension. We evaluated and 
compared the performance of NTA and VC3100 for precise measurements of nanoparticles. 
Since NTA is a scattering based technique, refractive index (RI) of the nanoparticles plays an 
important role in the brightness of measured nanoparticles. Nanoparticles with higher RI (1.59) 
such as polystyrene (PS) nanoparticles lead to a stronger scattering signal. Therefore, It is 
essential to use suitable reference materials with similar refractive index as EVs to compare the 
performance of different techniques. We used silica nanoparticles with the RI of 1.46 as the 
reference nanoparticles provide the most appropriate surrogate of EVs (RI of 1.4) [30–32]. The 
size distribution of the nanoparticles was first characterized by scanning electron microscopy 
(SEM) and NTA (Figure 4.3). The nanoparticle samples (200, 100, and 50 nm) are not perfectly 
monodispersed, and variations in their size were observed using both SEM and NTA. 
 






























































































Figure 4.3 - Size Characterization of 200 and 100 nm Silica Nanoparticles and 50 nm Polystyrene (PS) 
Nanoparticles. 
(A) Scanning electron microscopy images and (B) Size distribution using nanoparticle tracking analysis 
(NTA). 
 
In addition to the refractive index, the brightness of the scattering particles in NTA depends on 
nanoparticles' size. The scattering intensity of nanoparticles is proportional to the sixth power 
of their diameter [18,33]. Therefore, for nanoparticles with equal refractive indices, smaller 
particles scatter less light and are harder to detect compared to larger ones (Figure 4.4-A). NTA 
is designed to give the operator the power to obtain accurate measurements by several 
adjustment steps such as camera level during the video recording and tracking analysis. The 
effect of camera level on the concentration of 200, 100, and 50 nm nanoparticles was evaluated 
by systematically changing the camera level while keeping the other parameters constant. 
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Figure 4.4 - Effect of Camera Level on Detection of 200 and 100 nm Silica Nanoparticles and 50 nm 
Polystyrene (PS) Nanoparticles. 
(A) Nanoparticle tracking analysis (NTA) video frame and (B) Quantitative analysis of the camera level 
effect on the detection of nanoparticles. 
 
Adjustments to the camera level did not have any significant effect on the detected 
concentration of 200 and 100 nm particles (Figure 4.4-B). However, adjustments to the camera 
level revealed a concerning effect on 50 nm PS nanoparticles concentration measurements. 
NTA was not able to detect 50 nm PS nanoparticles when the camera level was decreased to 
10. The 200 and 100 nm nanoparticles scatter sufficient light such that changes to the camera 
level does not significantly affect the measured concentration. However, 50 nm nanoparticles 
scatter much less light compared to larger particles so the adjusted camera level plays an 
essential role in the measured concentration. This result illustrates the importance of the 
camera level in the detection of smaller EVs. It is important to note that NTA (CL 10) is not able 






























































Figure 4.5 - Performance Comparison of NTA and VC3100 for Accurate Quantification of Nanoparticles 
in Polydisperse Samples. 
NTA plots of mixtures with 1 to 1 ratio of (A) 200 and 100 nm nanoparticles, (B) 100 and 50 nm 
nanoparticles, (C) 200 and 50 nm nanoparticles, and (D) 200, 100, and 50 nm nanoparticles. (E) 
Quantitative analysis of different mixtures of nanoparticles with 1 to 1 ratio. (F) Quantitative analysis of 
mixtures of 200, 100, and 50 nanoparticles with different ratios. Quantitative analysis of mixtures of 
nanoparticles with different ratios using the VC3100 (G) 200 and 100 nm nanoparticles, (H) 100 and 50 
nm nanoparticles, (I) 200 and 50 nm nanoparticles, and (J) 200, 100, and 50 nm nanoparticles. 
 
The performance of NTA for measuring the concentration of polydisperse samples was 
evaluated. Mixtures of 200/100, 100/50, and 200/50 nm at a 1:1 ratio were first measured 
using the same instrument settings. In all 3 samples, the NTA failed to measure the 
concentration of smaller nanoparticles in the mixture accurately (Figure 4.5). This is due to a 
phenomenon that is referred to as the "masking effect". The intense light scattering of larger 
nanoparticles makes the smaller nanoparticles more challenging to detect and prevents some 
of them from being tracked by the software (Figure 4.5-[A-C]) [16,32,34]. This masking effect 
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was significant in the mixtures with 50 nm nanoparticles (Figure 4.5-A, B, and C). Quantitative 
analysis of the concentrations individually and combined illustrated inaccuracy in the resulting 
concentration measurements (Figure 4.5-E). In fact, the 50 nm nanoparticles were barely 
detected in the 200/50 nm mixture. In the next iteration, a mixture of 50/100/200 nm 
nanoparticles with a 1:1:1 ratio was measured using the same instrument settings. The masking 
effect was observed again and 50 nm nanoparticles were barely detectable in the mixture of 3 
different size nanoparticles by NTA (Figure 4.5-D). 
 
 
Figure 4.6 - Masking Effect in Different Ratios of 200,100, 50 nm Nanoparticles Mixtures. 
Mixture of 50; 100; 200 nm nanoparticles with (A) 4;1/2;1/2, (B) 8;1/2;1/2, (C) 8;1/5;1/5, and (D) 
8;1/10;1/10 ratios. 
  
















































































We hypothesized that if the reason for masking was the presence of larger nanoparticles, by 
increasing the ratio of 50 nm nanoparticles to 100 and 200 nm particles then the masking effect 
should be less significant. To test this hypothesis, the ratio of nanoparticles in the mixture was 
systematically changed, and the samples were measured by NTA. The concentration of 50 nm 
nanoparticles was increased while the concentrations of 100 and 200 nm nanoparticles were 
systematically decreased. By increasing the ratio of 50 nm to 100 and 200 nm nanoparticles, 
signals from 50 nm nanoparticles increased and at high ratios approached the expected 
concentration values (Figure 4.6). However, even as the number of 50 nm nanoparticles 
approached 80 times the levels of 100 and 200 nm particles, they were still not fully 
represented by NTA (Figure 4.5-F).  
Similar to NTA, the performance of the VC3100 for the concentration measurements of 
polydisperse samples was also evaluated. Initially, mixtures of 2 different size nanoparticles 
with different ratios were first tested. In all samples tested, the concentrations in polydisperse 
samples demonstrated an accurate enumeration of particles within different mixed ratios 
(Figure 4.5-[G-I]). Subsequently, samples with 50, 100, and 200 nm nanoparticles in 4 separate 
ratios were tested on the VC3100. The concentration analysis of samples individually and 
combined showed no evidence of underestimation of the concentration (Figure 4.5-J). In 
aggregate, and in contrast to NTA, measurements using the VC3100 did not appear to be 
affected by the masking effect. These data support the VC3100 as a powerful platform for more 




4.4.3 Quantification of Extracellular Vesicles by VC3100  
In this study, commercially available purified EV samples derived from urine of healthy donors 
were purchased and tested. As the VC3100 is a fluorescence-based technique, quantification 
can only be achieved by labeling EVs with a fluorescent dye compatible with the system. 
Urinary EVs were labeled by CellMask Orange (CMO), a lipophilic dye that labels the lipid 
membrane of EVs and were analyzed on the VC3100 in a no-wash assay. In this assay, with 
proper controls, CMO labeled urinary EVs were successfully quantified by the VC3100 without 
conducting a washing step. To confirm the detection of individual vesicles, the EV samples were 
serially diluted and their concentrations were measured using the VC3100. Similar to PS 
nanoparticles, a linear count consistent with the dilution was observed, indicating the 
successful enumeration of individual EVs (Figure 4.7-A). For concentrations near the upper 
detection limit of the VC3100, the sample counts were lower than predicted due to the 
coincidence. Finally, in the swarm region, the measured concentration of EVs dropped when 
the core stream was saturated with EVs as expected (Figure 4.7-A). 
Next, the utility of the VC3100 for measuring EVs from different sources was evaluated. Purified 
EVs derived from urine, serum, saliva, plasma, HEK293 conditioned medium, and B16F10 mouse 
cell line. EVs from different sources of EVs were successfully quantified by the VC3100 (Figure 
4.7-B). As suggested by "MIFlowCyt-EVs; a framework for standardized reporting of extracellular 
vesicle flow cytometry experiment," published in 2020 [29], different assay controls were 
examined to support the hypothesis of single vesicle detection. Isolated EV samples from 
different sources can be contaminated with non-EV complexes and have the potential to be 
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labeled and counted as positive EV events. Therefore, Triton X-100 was used to lyse their 
phospholipid membranes to determine whether the measured events were membrane-
enclosed vesicles or other non-EV complexes. Here, CMO labeled EVs were lysed with 1% Triton 
X-100 and were measured by the VC3100. For all sources of EVs tested, the number of detected 
events dropped to the lower detection limit of the VC3100, supporting the hypothesis that 
intact membrane-enclosed vesicles were being enumerated prior to the treatment (Figure 4.7 
and Figure 4.8).  
 
Figure 4.7 - Quantification of Extracellular Vesicles from Different Sources by the VC3100. 
(A) Serial dilution of urinary EVs labeled with CMO. (B) Detection of CMO labeled EVs from different 
sources before and after treatment with 1% Triton X-100. (C) CMO labeling of treated EVs with 1% 
Triton X-100. Peak histogram of (D) Buffer only control, (E) EVs only control, (F) CMO only control, (G) 
CMO labeled EVs from urine, (H) Triton X-100 treating of CMO labeled EVs, and (I) CMO labeling of 
Triton X-100 treated EVs. 
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To evaluate the possibility of confounding membrane fragments with intact EVs, unlabeled EVs 
were also treated by Triton-X100 and then labeled with CMO (Figure 4.7-C). Similarly, the 
number of detected events decreased to the same level as controls, which demonstrated that 
the VC3100 could only detect intact CMO labeled EVs. The peak histograms from 1 second of 
the measurements are illustrated for; the buffer only (Figure 4.7-D), EVs only (Figure 4.7-E), 
CMO dye only (Figure 4.7-F), CMO urinary EV sample (Figure 4.7-G), Triton X-100 treated CMO 
labeled EVs (Figure 4.7-H), and CMO labeled Triton X-100 EVs (Figure 4.7-I). 
 
 
Figure 4.8 - Triton X-100 Treatment of EVs from Different Sources. 
Peak histogram of (A) CMO labeled EVs from different sources, (B) Triton X-100 treating of CMO 
labeled EVs from different sources, and (C) CMO labeling of Triton X-100 treated EVs from different 






































































































































































































[ CMO + EVs ]  + Triton X-100
[ EVs + Triton X-100 ] + CMO






4.4.4 Protein Profiling of Individual EVs by VC3100  
In addition to quantification of EVs by CMO labeling, they can be further characterized using 
fluorochrome-conjugated antibodies. This allows identifying marker expression level and 
analyzing different subsets of EVs. Purified urinary EVs were labeled using phycoerythrin (PE) 
conjugated monoclonal antibodies against three different tetraspanins; CD9, CD63, and CD81 as 
common exosome markers. As previously proposed, control experiments such as buffer only, 
unlabeled EVs, and PE conjugated antibodies only (Figure 4.9) were tested to confirm that the 
detected events are individual EVs and not false positive signals.  
 
Figure 4.9 - Control Samples for Protein Profiling of Extracellular Vesicles. 
Peak histograms of (A) Buffer only control, (B) EVs only control, (C) PE-CD9 antibody only control, (D) 
PE-CD63 antibody only control, and (E) PE-CD81 antibody only control. 
 
Subpopulations of EVs were effectively identified by the VC3100 without a post labeling 
washing step. The peak histograms of isotype control only and PE conjugated labeled urinary 
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tested controls such as isotype control antibody labeling. The total number of urinary EVs was 
quantified by CMO labeling and the expression levels of different tetraspanins were identified; 
27.4 % were found to express the CD63 surface protein, 5.3 % positive for CD81 and 4.3 % for 
CD9 (Figure 4.10-E). To further confirm the detection of individual PE conjugated antibody 
labeled EVs, a dilution series of urinary EVs in two-fold steps was evaluated. The number of 
positive events detected of PE-CD63 labeled urinary EVs, decreased proportionally with the 
dilution factor, and resulted in the same calculated concentration at each dilution (Figure 4.10-
F). Therefore, the VC3100 can be successfully used for protein profiling of heterogenous EV 
samples with no washing step to remove the unbound dyes. 
 
Figure 4.10 - Protein Profiling of EVs by VC3100. 
Peak histogram of (A) Isotype control sample, (B) PE-CD9 positive urinary EVs, (C) PE-CD63 positive 
urinary EVs, and (D) PE-CD81 positive urinary EVs. (E) Quantitative analysis of tetraspanins positive 
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4.5 Discussion  
Flow cytometry based approaches hydrodynamically focus the sample flow in the center of 
sheath fluid to focus particles to pass the laser spot one by one. However, at high 
concentrations, two or more nanoparticles can pass the laser spot spontaneously, especially 
when the samples concentrations are unknown. As a result, the signals is detected as single 
event and separate events are no longer distinguishable. This phenomena is known as 
coincidence or swarm which leads to inaccurate concentration measurements and is one of the 
main challenges in flow cytometry approaches for quantifying and analyzing nanoparticles 
[5,24,25]. In order to study this phenomena, serial dilution has been proposed as the 
appropriate control assay [29]. We evaluated the possibility of random coincidence and swarm 
detection in the Virus Counter 3100 using 200, 100, and 50 nm PS nanoparticles. We found that 
event counts were proportional to the dilution factors in the linear region (5×105 - 5×108 
particles/mL) suggesting the detection of individual nanoparticles. However, as the samples 
concentrations approached the upper detection limit of the VC3100, random coincidence was 
observed due to the presence of two or more nanoparticles in front of the laser leading to 
underestimation of the concentration measurements. For even higher concentrations of 
nanoparticles, the core stream was saturated with nanoparticles and elevated baseline values 
were observed. This led to a drop in the concentration of the samples and caused inaccurate 
measurements (Figure 4.2). Therefore, serial dilution is an important and necessary control 




Nanoparticle tracking analysis (NTA) has been extensively used in the EV field for determining 
the size and concentration of nanoparticles. NTA uses laser light scattering microscopy with a 
charge-coupled device (CCD) camera. In short, after introducing the sample into the system, the 
movement of particles is recorded from scattered light. The scattering centers of the particles 
are tracked simultaneously but individually by the software. Based on the Brownian motion of 
the particles, the diffusion coefficient of each tracked particle is calculated. Using the Stokes-
Einstein equation, the software calculates and reports the size of tracked particles, assuming 
they are spherical. The concentration of nanoparticles in the sample is reported based on the 
number of tracked particles in the recorded video [16,32,34].  
We compared the performance of NTA with VC3100 using reference nanoparticles. Polystyrene 
(PS) nanoparticles are commonly used as the reference material for EVs in comparison studies 
as well as calibration in flow cytometry. However, because EVs have a refractive index (RI) of 1.4, 
it has been suggested that silica nanoparticles, with RI of 1.46, maybe better suited as the 
appropriate reference materials as an alternative to PS nanoparticles (RI 1.59).[41–43] 
Therefore, 200 and 100 nm silica nanoparticles were used as the reference nanoparticles. It's 
important to mention that 50 nm polystyrene nanoparticles were used due to the challenges in 
manufacturing silica nanoparticles smaller than 100 nm. 
Different parameters need to be adjusted to optimize detection of nanoparticles using NTA. 
These parameters can be divided into video recording and tracking analysis categories. Camera 
level (CL) is one of the video recording parameters that can be adjusted by the operator. This 
defines the sensitivity of the camera. Detection threshold (DT) is adjusted after the recording 
and before analysis. This establishes the minimum intensity required to establish the detected 
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event as a particle. In other words, the DT separates the signal from the noise.[29,44] The effect 
of the camera level on the detection of nanoparticles was systematically evaluate. The 
adjustment of the camera level did not have any significant effect on the detection of 200 and 
100 nanoparticles. However, 50 nm nanoparticles were not detected by NTA when the camera 
level was decreased to 10 (Figure 4.4). This can lead to variations in measurements between 
samples to samples and also shows that NTA is an operator dependent technique.   
We evaluated the performance of NTA for accurate measurements of nanoparticles in 
polydisperse samples using mixtures of 200, 100 and 50 nm nanoparticles. We found that NTA 
measurements are affected by the masking effect caused by the presence of larger 
nanoparticles in polydisperse samples leading to inaccurate measurements. In all samples 
tested, 50 nm nanoparticles were not accurately detected by NTA due to the masking effect 
caused by the presence of larger nanoparticles in polydisperse samples (Figure 4.2 and Figure 
4.6). The observed inaccurate measurements by NTA is concerning when precise quantification 
of heterogenous EV samples is needed. As opposed to NTA, VC3100 showed precise and 
accurate measurements of nanoparticles with no evidence of the masking effect suggesting that 
the VC3100 is a reliable technique for quantification of nanoparticles in heterogenous samples 
such as EVs (Figure 4.2). 
As the VC3100 is a fluorescence-based technique, quantification can only be achieved by 
labeling EVs with a fluorescent dye compatible with the system. Fluorescent dyes can be 
categorized into three types; lipid membrane dyes, luminal dyes and protein labeling dyes. Lipid 
membrane dyes such as the PKH family have been extensively used as a generic marker in the 
field for uptake, biodistribution and characterization studies [15,35,36]. However, in recent 
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years, a couple of studies have shown artifacts such as formation of PKH nanoparticles which 
are indistinguishable in terms of size and fluorescent intensity from PKH labeled EVs which can 
lead to false positive signals [22,35]. In addition, it has been recently shown that PKH labeling 
can affect the physical properties of EVs and results in an increase in the size of labeled EVs 
which may affect the uptake, biodistribution and characterization results [37]. CellMask Orange 
is a lipophilic dye that has been used for labeling EVs and fluoresces when inserted into a lipid-
membranes. Cornell-Morris et al. showed that CellMask Orange (CMO) dye can be used for 
analysis of EVs by NTA using the instrument’s fluorescence mode [38]. The authors further 
found that CMO does not affect the size of EVs compared to unlabeled EVs by NTA and unlike 
the PKH family, does not form micelles. 
In recent years, several studies have utilized high sensitivity fluorescent based flow cytometry 
for analyzing EVs. However, one of the biggest challenges in fluorescence mode is the 
contribution of light from unbound dye molecules to the background signal which can decrease 
the signal to noise ratio [22,24,25]. Therefore, flow cytometry analysis of EVs typically requires a 
post labeling washing step to remove the unbound dye molecules for accurate analysis. 
Different techniques such as ultracentrifugation [35], density gradient [5,24], size exclusion 
chromatography [22], and filtration [39–41] can be used for removing the excess dye from 
fluorescently labeled EV samples. However, the washing steps are time consuming and 
expensive and can cause sample loss and aggregation of EVs.[21] 
CMO labeled EVs derived from different sources such as plasma, urine, saliva, serum, HEK293 
conditioned media and B16F10 mouse cell line were successfully quantified by the VC3100 with 
no washing assay. In order to confirm the detection of individual EVs, different control assays 
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were performed such as serial dilution of CMO labeled EVs. Control samples such as buffer only, 
CMO dye only, and unlabeled EVs only showed a concentration below the lower limit of the 
VC3100. Detergent treatment control is another important assay to confirm the detection of 
membrane enclosed vesicles. CMO labeled EVs were treated by 1% Triton-X100 and measured 
by the VC3100. The number of detected events for EV samples from all sources tested 
significantly dropped after the treatment, confirming that the lipid membrane particles were 
detected before the treatment (Figure 4.7 and Figure 4.8). 
Specific subtypes of EVs may play important roles in distinct functions. For instance, surface 
proteins of EVs such as tetraspanins (CD9, CD63, and CD81) are involved in uptake of EVs by the 
recipient cell, protection of them from phagocytosis, and their circulation clearance. However, 
since EVs are highly heterogenous in size and surface proteins, changes in the expression level 
of a specific marker could be easily masked in bulk analysis.[7,9] Therefore, a fast, specific, 
reliable technique is required for protein profiling of EVs in diagnostic and therapeutic 
applications.  
The fluorescent intensity due to surface marker labeling depends on (i) the expression level of 
the target proteins, (ii) the efficiency of the labeling process, (iii) the light source excitation 
strength and the fluorescent dye quantum yield.[42–45] Successful protein profiling of urinary 
EVs labeled with PE-conjugated tetraspanins (CD9, CD63, and CD81) was further observed by 
the VC3100 with necessary control assays such as the isotype control (Figure 4.9 and Figure 
4.10). This result suggests that the VC3100 can be used for accurate and standardized 
quantification and phenotype analysis of EVs as an important factor for biomarker profiling and 
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therapeutic applications. In summary, this study has determined the VC3100 as a highly reliable 
and sensitive technique for the robust quantification and characterization of EVs (Figure 4.11).  
 




































4.6 Future Directions 
4.6.1 Multiparametric Analysis  
VC3100 is capable of detecting nanoparticles on two fluorescent channels, therefore, as a 
future direction, multiparametric analysis can be performed to investigate the co-expression of 
CD9, CD63, and CD81. This can help to better understand the phenotype of EVs and can provide 
valuable information for biomarker profiling regarding the heterogeneity of EVs.  
4.6.2 Sizing by VC3100  
Particle size and distribution of nanoparticles such as EVs are one of the important physical 
properties that are involved in uptake and biodistribution studies. Conventional transmission 
electron microscopy (TEM) have been widely used for studying the size and morphology of EVs. 
However, the sample preparation steps before imaging such as dehydration, chemical fixation 
and staining can affect the size and morphology of EVs. Cryo-electron microscopy is more 
reliable than conventional EM and does not require the mentioned sample preparation steps, 
hence preserves the physical properties of EVs. However, imaging techniques such as EM and 
AFM are not statistically powerful [14]. 
Single EV analysis techniques such as flow cytometry and NTA have been used for determining 
size. However, EVs are below the detection range of these techniques due to their small size 
and low refractive index. It is not clear if all sizes of EVs can be successfully detected by flow 
cytometry. The smallest size nanoparticles detected varies from system to system or it hasn’t 
been reported in many of flow cytometry based studies. Van der pol et al. investigated the 
 132 
 
minimum detectable vesicle size of widely used techniques in the field [32]. The authors 
reported that the minimum detectable vesicle sizes were 270-600 nm for conventional flow 
cytometry and 150-190 for dedicated flow cytometry for detection of sub-micrometer particles. 
In this aim, we also showed that masking effect is a major challenge in quantification of 
nanoparticles in heterogenous samples such as EVs by NTA. Since NTA cannot detect all of EVs, 
therefore the size distribution results are misinterpreted and inaccurate.  
In the last aim, we found that nanoparticles can be quantified accurately and precisely by the 
Virus Counter 3100. Another potential of the VC3100 that needs to be explored in detail, is the 
capability of this technique for identifying the size of nanoparticles. This can be achieved by 
analyzing the raw data from the detected events. Particularly, peak characteristics, such as peak 
height and width, can be correlated to nanoparticles' physical properties, such as size. Proof of 
concept experiments showed promising results in order to identify the size of nanoparticles by 
the VC3100, which are fully explained here;  
4.6.2.1 Peak Height 
Peak height represents the intensity of a signal from a detected event and the peak height’s 
unit is voltage. We first studied and compared the peak height values in monodisperse samples 
of 50, 100, and 200 nm nanoparticles. The Peak height frequency plots of these nanoparticles 
can be seen in Figure 4.12 with a bin width set to 0.5 V. In monodisperse samples of these 
nanoparticles, the peak height values were different, suggesting that peak height can be used 




Figure 4.12 - Peak Height Values in Monodisperse Samples of 50, 100, and 200 nm Nanoparticles. 
In order to test this hypothesis, mixtures of two nanoparticles with one to one ratios were 
made and the peak height values were studied. As shown in Figure 4.13, in all these mixtures 
tested, two distinguished peaks can be observed and correlated to different size nanoparticles. 
Quantitative analysis of the samples also showed no significant difference between individual 
and combined samples. 
 
Figure 4.13 - Peak Height Values in Mixture Samples of Two Nanoparticles.   
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Furthermore, A mixture of all three nanoparticles (200, 100 and 50 nm) with the same 
concentrations was also tested (Figure 4.14). Similarly, observing three distinguished peaks in 
the histogram and no significant difference in quantitative analysis suggested that peak height 
can be used for determining the size of nanoparticles. It is important to note that the peak 
height value depends on the size of nanoparticles and the number of fluorescein dye molecules 
per particle.  
 
Figure 4.14 - Peak Height Values in Mixture Samples of Three Nanoparticles.   
 
4.6.2.2 Peak Width 
A better alternative to the peak height is the peak width. Peak width’s unit is second which 
represents the amount of time that a particle spends in front of the laser (dwelling time). The 
bigger the nanoparticles, the broader the peaks are, therefore, peak width can directly 
represent the size of nanoparticles. Similar set of experiments was performed, and the peak 
width values were studied. The peak width is the amount of time that a particle travels in front 
of the laser. The peak width values in monodisperse samples of 50, 100, and 200 nm 
nanoparticles can be found in Figure 4.15.  







































Figure 4.15 - Peak Width Values in Monodisperse Samples of 50, 100, and 200 nm Nanoparticles. 
When mixtures of 2 nanoparticles were tested, different size of nanoparticles were easily 
distinguished based on their peak width values (Figure 4.16). Similarly, peak histogram and 
quantitative analysis of the mixture of all nanoparticles suggested that peak width values can 
be correlated to the size of nanoparticles.  
 
Figure 4.16 - Peak Width Values in Mixture Samples of Two Nanoparticles.   
Similarly, the mixtures of 3 nanoparticles (50/100/200 nm) were made and tested by the 
VC3100. The peak width values in the mixtures were evaluated and different size of 
nanoparticles were distinguishable (Figure 4.17).  
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Figure 4.17- Peak Width Values in Mixture Samples of Three Nanoparticles.   
4.6.2.3 Proposed Set of Experiments 
To examine the performance of the VC3100 in identifying size of nanoparticles, a series of 
monodisperse silica fluorescent nanoparticles of different sizes ranging from 20 to 300 nm 
could be purchased and used as the size reference materials. The size of the nanoparticles will 
be first characterized by electron microscopy and NTA. Then, the fluorescent nanoparticle 
samples could be tested individually first, and their peak width and height could be determined. 
A calibration curve could be obtained by correlating the size of fluorescent nanoparticles to the 
peak height and width values. As the next step, different mixtures of these nanoparticles with 
known ratios could be made and tested by the VC3100. Comparing the peak height and width 
values of nanoparticles individually and combined, the feasibility of the VC3100 for sizing could 
be fully confirmed, as the preliminary results suggested.  
Similar to this proposed set of experiment, Tian et al. recently developed a high sensitivity flow 
cytometry (HSFCM) which was used successfully for protein profiling and sizing of EVs [7]. The 
authors examined the performance of HSFCM for sizing of nanoparticles using a series of 
monodisperse silica nanoparticles (47, 59, 74, 94 and 123 nm). Since, the HSFCM is a scattering 






































based technique, the authors had to correct the deviation induced by the refractive index 
mismatch between silica nanoparticles and EVs to make the calibration curve. But this should 





The missing element in current solutions used to enumerate and characterize EVs lies in the fact 
that there is no one platform that provides the holistic data required for full characterization. 
This would include the combined attributes of pan enumeration of EVs or exosomes, differential 
sizing and enumeration of those sub-populations within different preparations of EVs, multi-
parametric phenotypic analysis, measures of cargo and, finally, controls to exclude cell 
fragments. Expanded probes and especially measure of cargo may represent the most pressing 
needs. Achieving this requires surmounting the challenges that are presented by the small size 
and heterogeneity of EVs. In this study, we tested the capability of the flow cytometry-based 
nanoparticle analyzer, Virus Counter 3100, in the combined areas of enumeration of particles as 
small as 50 nm (in the absence of scatter), compatibility with polydisperse samples, and 
compared this to the gold standard in the field, NTA.  We expanded on this to include a pan EV 
stain as well as phenotypic measure of some of the more common exosome markers. First, the 
detection and enumeration of individual nanoparticles (50 to 200 nm) was confirmed by 
studying serially diluted samples. Appropriate sample dilution was shown to be critical to avoid 
coincidence and swarm detection caused by high sample concentration. The performance of the 
VC3100 was then compared to NTA and the former successfully demonstrated accurate 
quantification of nanoparticles in polydisperse samples such as EVs. NTA demonstrated issues 
for accurate measurements of mixture samples due to the masking effect of smaller 
nanoparticles from the presence of larger ones. In other studies, EVs from six different sources 
were fluorescently labeled by CellMask Orange and were successfully quantified by the VC3100 
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without a post labeling washing step. Additionally, the expression level of tetraspanins (CD9, 
CD63, and CD81) were effectively measured using the VC3100. Future work with alternative 
probes could potentially label cargo as well as surface antigens using this methodology. These 
results suggest that the VC3100 is an emerging technology that may be further refined to 
provide information on sizing, to expand on the number of parameters simultaneously 
measured, to ultimately emerge as a technology capable of simultaneously addressing  a 
number of desired parameters.  
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5 Conclusion and Contributions 
In the first aim, we developed a filtration based microfluidic system termed as tangential flow 
for analyte capture (TFAC), which is a modified version of tangential flow filtration. we 
observed that normal flow filtration (NFF) of undiluted plasma on ultrathin nanomembranes 
leads to rapid formation of a protein cake which also stops the purification process. As opposed 
to NFF, we found that tangential flow filtration of plasma can be used to capture extracellular 
vesicle (EVs) on the pores of ultrathin nanomembranes with minimal contamination. We 
further found that ultrathin nanomembranes are ideally suited for purification of EVs using 
TFAC compared to conventional thickness membranes since, 1) ultrathin nanomembranes 
operate with two orders of magnitude lower pressure, which minimizes concerns of damaging 
EVs during filtration, and 2) the 1 -10 µm thickness of conventional nanomembranes can cause 
trapping the nanoparticles inside the pore channels which leads to loss of sample and low yield. 
The performance of TFAC on NPN needs to be further optimized to increase the purification 
yield and purity by coating the surface of membranes to minimize non-specific interactions,  
recirculating EV samples, and adjusting the operating condition and device design. This project 
titled “Tangential Flow Microfluidics for the Capture and Release of Nanoparticles and 
Extracellular Vesicles on Conventional and Ultrathin Membranes” was published in the journal 
of Advanced Materials Technologies in 2019. 
In another study collaborating with Dr. James McGrath and his laboratory at the University of 
Rochester, we further studied and compared the critical flux behavior of the track-etch 
membrane and ultrathin nanomembrane microfluidic devices. Studying the critical flux 
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behavior of ultrathin nanomembranes is essential for TFAC purification of EVs from complex 
biological fluids with high concentrations of proteins. We found that the ultrathin nature of 
NPN membranes enables 10 times higher critical flux than conventional thickness membranes 
under the same operating condition. This study titled “Critical Flux Behavior of Ultrathin Silicon 
Nanomembranes” was published in 2020 in the journal of Separation and Purification 
Technology. 
Additionally, in our lab, we recently reported the fabrication of ultrathin free-standing 
nanoporous membranes using nanosphere lithography (NSL) which offers a pore size control 
over large area at an affordable cost. We evaluated the performance of NSL nanomembranes 
for separating a subpopulation of EVs based on size. We found an effective size cut-off of 300 
nm with the majority of EVs < 200 nm, suggesting potential for studying subpopulations of EVs. 
The NSL technique can be extended for fabrication of nanopocket membranes, a novel type of 
membranes with pores patterned as a bowl like structure with a hole at the bottom. 
Nanopocket membranes with different dimensions can be fabricated and employed in TFAC for 
separation of subpopulations of EVs. This study titled “Use of Nanosphere Self-Assembly to 
Pattern Ultrathin Membranes for the Study of Extracellular vesicles” was published in the 
journal of the Nanoscale Advances in 2020.  
Related to the second aim, we systematically studied the effect of PKH labeling as the most 
commonly used fluorescent dye, on the size of extracellular vesicles. Nanoparticle tracking 
analysis (NTA) was employed to determine the size of EVs before and after labeling. We found 
that PKH labeling does not preserve the size of EVs which can alter the uptake and 
biodistribution studies. As opposed to the PKH labeling, CFSE dye (luminal labeling approach) 
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does not affect the size of EVs after labeling and is a more reliable technique for fluorescent 
labeling of EVs. Therefore, more attention needs to be paid to the effect of fluorescent labeling 
approaches on the size of EVs. In addition to preserving the size of EVs, an ideal generic 
fluorescent dye molecule must label all and only EVs, have minimal background signal, have a 
high signal to noise ratio, and preserve the native biological behavior of EVs. This project titled 
“Systematic Evaluation of PKH Labeling on Extracellular Vesicles Size Using Nanoparticles 
Tracking Analysis” was published in 2020 in the journal of Scientific Reports. In another 
contribution related to fluorescent labeling of extracellular vesicles, we were invited to write a 
book chapter on fluorescent labeling approaches of EVs. This book chapter titled “Fluorescent 
Labeling of Extracellular vesicles” was recently accepted for publication in Methods in 
Enzymology.  
In the third aim, since EVs and viruses share many common features, we evaluated the efficacy 
of a virus detection technology for EVs. Virus counter 3100 (VC3100) is a fluorescence based 
approach with similar principles as flow cytometry and is purposely built for detection of 
nanoparticles such as viruses. We found that NTA, the most commonly used technique for 
determining size and concentration of EVs, is not capable of precise measurements of the 
concentration in heterogenous samples of nanoparticles such as EVs due to the masking effect. 
We showed that the virus counter is superior for accurate concentration measurements in 
heterogeneous mixtures of particles compared to NTA. We further observed that CellMask 
Orange can be used to successfully quantify EVs derived from different sources without a post-
labeling washing step. We also found that the virus counter is capable of protein profiling of EVs 
to determine their expression level. The possibility of using the virus counter for 
 146 
 
multiparametric analysis of EVs to investigate the co-expression of markers needs to be further 
explored. Furthermore, the capability of this technique for determining the size of 
nanoparticles based on the peaks characteristics of individual events needs to be studied in 
details. This study titled “An Emerging Fluorescence-Based Technique for Quantification and 
Protein Profiling of Extracellular Vesicles” is submitted in the journal of SLAS Technology and is 
currently under review.  
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